<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01072175</url>
  </required_header>
  <id_info>
    <org_study_id>113220</org_study_id>
    <nct_id>NCT01072175</nct_id>
  </id_info>
  <brief_title>Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 &amp; GSK1120212</brief_title>
  <official_title>An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the BRAF Inhibitor GSK2118436 in Combination With the MEK Inhibitor GSK1120212 in Subjects With BRAF Mutant Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, dose escalation study to investigate the safety, pharmacokinetics,
      pharmacodynamics and clinical activity of GSK2118436 and GSK1120212 in combination. This
      study is designed in four parts. In Part A, the effect of repeat doses of GSK1120212 on the
      pharmacokinetics of single dose GSK2118436, will be investigated prior to evaluating
      combination regimens. In Part B, the range of tolerated dose combinations will be identified
      using a dose-escalation procedure. In Part C, different dose combinations of GSK2118436 and
      GSK1120212 will be evaluated, based on results from the dose escalation cohorts. In Part D,
      the pharmacokinetics and safety of GSK2118436 administered as HPMC capsules alone and in
      combination with GSK1120212 will be evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During Part A, a cohort of subjects will receive a single dose of GSK2118436 alone (Day 1)
      and then repeat doses of GSK1120212 for (Day 2 through Day 15). The dose regimen of
      GSK1120212 will be continuous dosing. A second single dose of GSK2118436 will be administered
      on Day 15 concomitantly with GSK1120212. Day 16 through Day 28 will be a washout period,
      during which no study medication is administered. Starting on Day 29, subjects who elect to
      continue participation in the study will dose with GSK2118436. The dose of GSK2118436 after
      Day 29 may be altered based on emerging data from the first-time-in human study BRF112680.
      The dose may be increased to a dose level that has been completed and determined to be less
      than or equal to the maximum tolerated dose in that study.

      Part B of the study will enroll cohorts in escalating doses to identify a set of allowable
      doses to be expanded in Part C. Subjects will enrolled in a 3+3 cohort design, with
      provisional dose levels of both drugs. The decision regarding escalation to the next dose
      levels of GSK1120212 and GSK2118436 will be further guided by a Bayesian logistic regression
      model. The first cohort will start at low doses for both drugs. Doses up to 300 mg/day for
      GSK2118436 and up to 3 mg QD for GSK1120212 have been studied to date. The starting dose may
      be lowered based on emerging data from other studies and from Part A.

      Expansion cohorts will be enrolled in Part C at dose levels of GSK2118436 and GSK1120212 as
      defined in Part B. One of the selected doses may include GSK2118436 administered as
      monotherapy at a tolerable dose (less than or equal to the maximum tolerated dose) determined
      in BRF112680. Part C is a randomized open-label Phase II portion of the study, and will
      consist of expansion cohorts investigating 2 to 3 dose levels of GSK2118436 and GSK1120212
      dosing in combination, and GSK2118436 administered as monotherapy. Subjects will be assigned
      to treatment arms in a randomized fashion to compare tolerability and safety. Population PK
      parameters, clinical activity, durability of response and safety of GSK2118436 and GSK1120212
      dosed orally in combination and GSK2118436 as monotherapy will be evaluated.

      Part D will consist of evaluation of the pharmacokinetics of GSK2118436 HPMC capsules
      administered as monotherapy and in combination with GSK1120212. Pharmacokinetics of
      GSK2118436 will be assessed following a single dose on Day 1 and after repeat dosing (Day 21)
      and compared between combination and monotherapy. The pharmacokinetics of GSK1120212 will
      also be assessed. Safety, tolerability and clinical activity will also be evaluated in 4
      dosing cohorts. These cohorts may be expanded for additional safety data. Subjects will be
      randomized to different cohorts.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 26, 2010</start_date>
  <completion_date type="Anticipated">April 30, 2018</completion_date>
  <primary_completion_date type="Actual">May 31, 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of a Single Dose of Dabrafenib Administered Alone and in Combination With Trametinib in Part A</measure>
    <time_frame>Day 15</time_frame>
    <description>Blood samples for PK analysis of dabrafenib and its the metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) were obtained at pre-dose and at 1, 2, 3, 4, 6, 8, 10, and 24 hours after dabrafenib administration. From the plasma concentration-time curve, the PK parameter Cmax was determined by standard non-compartmental analysis using WinNonlin. Cmax data are reported as geometric least squares means.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (0-t) and AUC (0-inf) of Dabrafenib and Its Metabolites in Part A</measure>
    <time_frame>Day 15</time_frame>
    <description>Blood samples for PK analysis of dabrafenib and its metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) were obtained at pre-dose and at 1, 2, 3, 4, 6, 8, 10, and 24 hours after dabrafenib administration. AUC is defined as the area under the dabrafenib concentration-time curve as a measure of drug exposure. AUC (0-inf) is defined as the area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time. AUC (0-t) is defined as area under the concentration-time curve from time zero (pre-dose) to the last time of quantifiable concentration. Date are reported as geometric least square means.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) in Part B</measure>
    <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 103 weeks )</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury. Refer to the general Adverse AE/SAE module for a complete list of AEs and SAEs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With the Indicated Worst-case Grade (G) Change From Baseline in the Indicated Clinical Chemistry Parameters in Part B</measure>
    <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 103 weeks)</time_frame>
    <description>Clinical chemistry parameters were summarized according to National Cancer Institutes (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred. For clinical chemistry parameters that were not graded according to NCI CTCAE criteria, changes above (High) and below (Low) the normal range were evaluated. Clinical chemistry parameters included: hyponatremia, gamma glutamyltransferase (GGT), phosphorous inorganic, alkaline phosphatase, hyperglycemia, aspartate aminotransferase (AST), hypokalemia, albumin, alanine aminotransferase (ALT), total bilirubin, hyperkalemia, hypoglycemia, creatinine, lactate dehydrogenase, urea/blood urea nitrogen (BUN), bicarbonate, chloride, creatine clearance, total protein, uric acid, and troponin T.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With the Indicated Worst-case Grade Change From Baseline in the Indicated Hematology Parameters in Part B</measure>
    <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 103 weeks)</time_frame>
    <description>Hematology parameters were summarized according to NCI CTCAE grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred. For hematology parameters that were not graded according to NCI CTCAE criteria, changes above (High) and below (Low) the normal range were evaluated. Hematology parameters included: lymphocytes decreased, total neutrophils, hemoglobin decreased, white blood cell counts, platelet counts, monocytes, mean corpuscular hemoglobin concentration (MCHC), eosinophils, basophils, mean corpuscular hemoglobin, mean corpuscular volume, red blood cell count, hematocrit, and reticulocytes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With the Indicated Worst-case Change From Baseline in Heart Rate and Blood Pressure in Part B</measure>
    <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 103 weeks)</time_frame>
    <description>Blood pressure and heart rate were summarized according to NCI CTCAE grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to G3 or G4 occurred. Blood pressure measurement included systolic blood pressure (SBP, millimeters of mercury [mmHg]) and diastolic BP (DBP). Heart rate is the measure of heart beats per minute (bpm). Changes in heart rate, either decrease to &lt;60 bpm, change to normal or no change, or increase to &gt;100 bpm are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With BRAF Mutant Metastatic Melanoma With Best Overall Response as Assessed by the Investigator in Part C (Randomized)</measure>
    <time_frame>From the first dose of study medication to the first documented evidence of a confirmed complete response or partial response (up to approximately 47 weeks)</time_frame>
    <description>Best overall response is defined as complete response (CR: the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 millimeters [mm] in the short axis.) or partial response (PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]). Participants with unknown or missing responses were considered as non-responders. To be assigned a status of PR or CR, a confirmatory disease assessment should have been performed no less than 28 days after the criteria for response were first met. Response was evaluated by an investigator as per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With BRAF Mutant Metastatic Melanoma With Best Overall Response Assessed by Blinded Independent Central Review (BICR) in Part C (Randomized)</measure>
    <time_frame>From the first dose of study medication to the first documented evidence of a confirmed complete response or partial response (up to approximately 36 weeks)</time_frame>
    <description>Best overall response is defined as complete response (CR: the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 mm in the short axis.) or partial response (PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]). Participants with unknown or missing responses were considered as non-responders. To be assigned a status of PR or CR, a confirmatory disease assessment should have been performed no less than 28 days after the criteria for response were first met. Response was evaluated by BICR as per RECIST, version 1.1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With BRAF Mutant Metastatic Melanoma With Best Overall Response as Assessed by the Investigator in Part C (Crossover)</measure>
    <time_frame>From the first dose of study medication to the first documented evidence of a confirmed complete response or partial response (up to approximately 15 weeks)</time_frame>
    <description>Best overall response is defined as complete response (CR: the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 mm in the short axis.) or partial response (PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]). Participants with unknown or missing responses were considered as non-responders. To be assigned a status of PR or CR, a confirmatory disease assessment should have been performed no less than 28 days after the criteria for response were first met. Response was evaluated by an investigator as per RECIST, version 1.1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Response as Assessed by the Investigator and Blinded Independent Central Review (BICR) in Part C (Randomized)</measure>
    <time_frame>First documented evidence of PR or CR until the date of the first documented sign of disease progression or the date of death due to any cause (up to approximately 17 months)</time_frame>
    <description>Duration of response for participants with either a CR (the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 mm in the short axis.) or PR (at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]) is defined as the time from the first documented evidence of a PR or CR until the first documented sign of disease progression (PD) or death due to any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free Survival (PFS) as Assessed by the Investigator in Part C (Randomized)</measure>
    <time_frame>From the first dose of study medication to the earliest date of disease progression (PD) or death due to any cause (up to approximately 17 months)</time_frame>
    <description>PFS is defined as the interval between the first dose of study medication and the earliest date of PD or death due to any cause. PD was based on radiographic or photographic evidence, and assessments were made by the investigator according to RECIST, version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm. Participants who received anti-cancer therapy prior to the date of documented events, were censored at the last adequate assessment prior to the initiation of therapy. If the participant did not had a documented date of events, PFS and survival were censored at the date of the last adequate assessment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free Survival (PFS) as Assessed by the Blinded Independent Central Review (BICR) in Part C (Randomized)</measure>
    <time_frame>From the first dose of study medication to the earliest date of disease progression (PD) or death due to any cause (up to approximately 17 months)</time_frame>
    <description>PFS is defined as the interval between the first dose of study medication and the earliest date of PD or death due to any cause. PD was based on radiographic or photographic evidence, and assessments were made by the BICR according to RECIST, version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm. Participants who received anti-cancer therapy prior to the date of documented events, were censored at the last adequate assessment prior to the initiation of therapy. If the participant did not had a documented date of events, PFS and survival were censored at the date of the last adequate assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free Survival (PFS) as Assessed by the Investigator in Part C (Crossover)</measure>
    <time_frame>From the first dose of study medication to the earliest date of disease progression (PD) or death due to any cause (up to approximately 9 months)</time_frame>
    <description>PFS is defined as the interval between the first dose of study medication and the earliest date of PD or death due to any cause. PD was based on radiographic or photographic evidence, and assessments were made by the investigator according to RECIST, version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm. Participants received anti-cancer therapy prior to the date of documented events, and censored at the last adequate assessment, prior to the initiation of therapy. If the participant did not have a documented date of events, PFS and survival were censored at the date of the last adequate assessment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) in Part C (Randomized)</measure>
    <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 75 weeks)</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury. Refer to the general Adverse AE/SAE module for a complete list of AEs and SAEs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With the Indicated Worst-case Grade (G) Change From Baseline in the Indicated Clinical Chemistry Parameters in Part C (Randomized)</measure>
    <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 75 weeks)</time_frame>
    <description>Clinical chemistry parameters were summarized according to National Cancer Institutes (NCI) CTCAE grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3, Severe; Grade 4, Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to any grade, Grade 3 or Grade 4 occurred. For clinical chemistry parameters that were not graded according to NCI CTCAE criteria, changes above (High) and below (Low) the normal range were evaluated. Clinical chemistry parameters included: albumin, alkaline phosphate (ALKP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total Bilirubin, calcium, creatine kinase, creatinine, gamma glutamyltransferase (GGT), glucose, potassium, magnesium, sodium, inorganic phosphorus. Worst case change from Baseline was calculated as the post-Baseline value minus the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With the Indicated Worst-case Grade Change From Baseline in the Indicated Hematology Parameters in Part C (Randomized)</measure>
    <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 75 weeks)</time_frame>
    <description>Hematology parameters were summarized according to National Cancer Institutes (NCI) CTCAE grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3, Severe; Grade 4, Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to any grade, Grade 3 or Grade 4 occurred. For hematology parameters that were not graded according to NCI CTCAE criteria, changes above (High) and below (Low) the normal range were evaluated. Hematology parameters included: hemoglobin, lymphocytes, Total absolute neutrophil count (ANC), platelet count, white blood cells (WBC) count. Worst case change from Baseline was calculated as the post-Baseline value minus the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With the Indicated Worst-case Change From Baseline in Heart Rate and Blood Pressure in Part C (Randomized)</measure>
    <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 75 weeks)</time_frame>
    <description>Blood pressure were summarized according to National Cancer Institutes (NCI) CTCAE grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to G3 or G4 occurred.lood pressure measurement included systolic blood pressure (BP, millimeter of mercury [mmHg]) and diastolic BP (DBP). Worst case change from Baseline was calculated as the post-Baseline value minus the Baseline value. Heart Rate is the measure of heart beats per minute (bpm). Changes in heart rate, either decrease to &lt;60 bpm, change to normal or no change, or increase to &gt;100 bpm are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of a Single and Repeat Dose of Dabrafenib Alone and in Combination With Trametinib in Part D (Analyte=GSK2118436)</measure>
    <time_frame>Day 1 and Day 21</time_frame>
    <description>The PK parameter Cmax was assessed. Blood samples for PK analysis of dabrafenib were obtained at pre-dose Day 1 and Day 21 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours (24 hour on Day 1 only) post-dose administration. From the plasma concentration-time curve, the PK parameter tmax was determined by standard non-compartmental analysis using WinNonlin. Cmax data are reported as geometric least squares means.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Tmax of a Single and Repeat Dose of Dabrafenib Alone and in Combination With Trametinib in Part D (Analyte=GSK2118436)</measure>
    <time_frame>Day 1 and Day 21</time_frame>
    <description>tmax is defined as the time of occurence of Cmax. Blood samples for PK analysis of dabrafenib were obtained at Day 1 and Day 21 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 24 hours (24 hour on Day 1 only) post-dose administration. From the plasma concentration-time curve, the PK parameter tmax was determined by standard non-compartmental analysis using WinNonlin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (0-tau) and AUC (0-inf) of Single and Repeat Doses of Dabrafenib Alone and in Combination With Trametinib in Part D (Analyte=GSK2118436)</measure>
    <time_frame>Day 1 and Day 21</time_frame>
    <description>The PK parameters were determined for area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration AUC (0-tau) and from time zero (pre-dose) extrapolated to infinite time AUC (0-inf). Blood samples for PK analysis of the metabolites of dabrafenib were obtained at Day 1 and Day 21 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours (24 hour only on Day 1) post-dose administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) in Part D</measure>
    <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 61 weeks)</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event for possible drug-induced liver injury. Refer to the general Adverse AE/SAE module for a complete list of AEs and SAEs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With the Indicated Worst-case Grade (G) Change From Baseline in the Indicated Clinical Chemistry Parameters in Part D</measure>
    <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 61 weeks)</time_frame>
    <description>Clinical chemistry parameters were summarized according to NCI CTCAE grade, version 4.0. G1, Mild; G2, Moderate; G3, Severe; G4, Life-threatening or disabling; G5, Death. Data are presented for only those parameters for which an increase to G3 or G4 occurred. Changes above (High) and below (Low) the normal range were evaluated for parameters not graded. Included:hyponatremia,gamma glutamyltransferase (GGT),aspartate aminotransferase (AST),hyperglycemia,alkaline phosphatase,hypokalemia,alanine aminotransferase (ALT),phosphorus inorganic,creatine kinase,total bilirubin,albumin,hyperkalemia, hypomagnesemia,lipase,hypokalemia,hyponatremia,urea/blood urea nitrogen (BUN),bicarbonate,creatine clearance,chloride,C-reactive protein,total protein,uric acid,troponin I,direct bilirubin,creatine kinase MB mass, chloride,total protein,bicarbonate,uric acid,creatine clearance,lactate dehydrogenase. Worst case change from BL was calculated as the post-BL value minus the BL value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With the Indicated Worst-case Grade Change From Baseline in the Indicated Hematology Parameters in Part D</measure>
    <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 61 weeks)</time_frame>
    <description>Hematology parameters were summarized according to NCI CTCAE grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred. For hematology parameters that were not graded according to NCI CTCAE criteria, changes above (High) and below (Low) the normal range were evaluated. Hematology parameters included lymphocytes, total neutrophils, hemoglobin, white blood cell count, platelet count, monocytes, mean corpuscle hemoglobin concentration, eosinophils, basophils, mean corpuscle hemoglobin, mean corpuscle volume, red blood cell count, hematocrit, erythrocyte sedimentation, reticulocytes. Worst case change from Baseline was calculated as the post-Baseline value minus the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With the Indicated Worst-case Change From Baseline in Heart Rate and Blood Pressure in Part D</measure>
    <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 61 weeks)</time_frame>
    <description>Blood pressure were summarized according to National Cancer Institutes (NCI) CTCAE grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to G3 or G4 occurred.lood pressure measurement included systolic blood pressure (BP, millimeter of mercury [mmHg]) and diastolic BP (DBP). Worst case change from Baseline was calculated as the post-Baseline value minus the Baseline value. Heart Rate is the measure of heartbeats per minute (bpm). Changes in heart rate, either decrease to &lt;60 bpm, change to normal or no change, or increase to &gt;100 bpm are presented</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Steady State Concentration of Trametinib With Concomitant Administration of Dabrafenib in Part A</measure>
    <time_frame>Day 15 and Day 16</time_frame>
    <description>The steady state plasma concentration (Css) of trametinib with concomitant dabrafenib administration was assessed at Day 15 and Day 16. At steady state the amount of drug administered (in a given time period) is equal to the amount of drug eliminated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The AUC [0-tau] of Dabrafenib (DAB) and Its Metabolite in Combination With Trametinib (T) in Part B</measure>
    <time_frame>Day 15 and Day 21</time_frame>
    <description>Area under the concentration-time curve from time zero (predose) until the last time of quantifiable concentration (AUC [0-tau]) was assessed. Blood samples for PK analysis of dabrafenib and its the metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) were obtained at Day 15 pre-dose and Day 21 pre-dose and at 1, 2, 4, 6, and 8 hours post-dose administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-dose (Trough) Concentration at the End of the Dosing Interval (Ctau) and Maximum Plasma Concentration (Cmax) of Dabrafenib and Its Metabolite in Combination With Trametinib in Part B</measure>
    <time_frame>Day 15 and Day 21</time_frame>
    <description>Pre-dose (trough) concentration at the end of the dosing interval (Ctau) and maximum plasma concentration (Cmax) were assessed for plasma dabrafenib (DAB) following repeat dosing of DAB administered in combination with trametinib (T). The trough concentration is defined as the plasma level of a pharmaceutical product measured just before the next dose. Blood samples for PK analysis of the metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) of dabrafenib were obtained at Day 15 pre-dose and Day 21 pre-dose and at 1, 2, 4, 6, and 8 hours post-dose administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Tmax of Dabrafenib and Its Metabolite in Combination With Trametinib in Part B</measure>
    <time_frame>Day 15 and Day 21</time_frame>
    <description>The tmax is defined as the time of occurence of Cmax. Tha tmax was assessed for plasma dabrafenib (DAB) following repeat dosing of dabrafenib 75 and 150 mg BID administered in combination with trametinib. Blood samples for PK analysis of the metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) of dabrafenib were obtained at Day 15 pre-dose and Day 21 pre-dose and at 1, 2, 4, 6, and 8 hours post-dose administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The AUC (0-tau) Assessment of Trametinib in Combination With Dabrafenib in Part B (Analyte=GSK1120212)</measure>
    <time_frame>Day 15 and Day 21</time_frame>
    <description>AUC (0-tau) is defined as area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration. AUC (0-tau) was assessed for plasma trametinib following repeat dosing of trametinib in combination with dabrafenib. Blood samples for PK analysis of the metabolites of dabrafenib were obtained at Day 15 pre-dose and Day 21 pre-dose and at 1, 2, 4, 6, and 8 hours post-dose administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Ctau and Cmax Assessments of Trametinib in Combination With Dabrafenib in Part B (Analyte=GSK1120212)</measure>
    <time_frame>Day 15 and Day 21</time_frame>
    <description>Pre-dose (trough) concentration at the end of the dosing interval (Ctau) and maximum plasma concentration (Cmax) were assessed for plasma trametinib following repeat dosing of trametinib in combination with dabrafenib. Blood samples for PK analysis of the metabolites of dabrafenib were obtained at Day 15 pre-dose or Day 21 pre-dose and at 1, 2, 4, 6, and 8 hours post-dose administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Tmax Assessment of Trametinib in Combination With Dabrafenib in Part B (Analyte=GSK1120212)</measure>
    <time_frame>Day 15 and Day 21</time_frame>
    <description>The tmax is defined as the time of occurrence of Cmax. The PK parameter for tmax was assessed for plasma trametinib following repeat dosing of trametinib in combination with dabrafenib. Blood samples for PK analysis of the metabolites of dabrafenib were obtained at Day 15 pre-dose or Day 21 pre-dose and at 1, 2, 4, 6, and 8 hours post-dose administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With BRAFi-naïve Mutant Metastatic Melanoma With the Best Overall Response as Assessed by Investigator in Part B</measure>
    <time_frame>From the first dose of study medication to the first documented evidence of a confirmed complete response or partial response (up to 103 weeks)</time_frame>
    <description>Best overall response is defined as complete response (CR: the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 millimeter [mm] in the short axis.) or partial response (PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]). Participants with unknown or missing response were considered as non-responders. To be assigned a status of PR or CR, a confirmatory disease assessment should have been performed no less than 28 days after the criteria for response were first met. Response was evaluated by an investigator as per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. BRAFi-naïve participants were those with BRAF-mutation-positive melanoma who had not received prior therapy with a BRAF inhibitor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response as Assessed by the Investigator in Participants With BRAFi-naïve Mutant Metastatic Melanoma in Part B</measure>
    <time_frame>First documented evidence of PR or CR until the earlier of date of disease progression or date of death due to any cause (up to approximately 22 months)</time_frame>
    <description>Duration of response for participants with either a CR (the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 mm in the short axis.) or PR (at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]) is defined as the time from the first documented evidence of a PR or CR until the first documented sign of disease progression (PD) or death due to any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm. BRAFi-naïve participants were those with BRAF-mutation-positive melanoma who had not received prior therapy with a BRAF inhibitor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS) as Assessed by the Investigator in Participants With BRAFi-naïve Mutant Metastatic Melanoma in Part B</measure>
    <time_frame>From the date of first dose to the earliest date of disease progression (PD) or death due to any cause (up to approximately 22 months)</time_frame>
    <description>PFS is defined as the interval between the first dose of study medication and the earliest date of PD or death due to any cause. PD was based on radiographic or photographic evidence, and assessments were made by the investigator according to RECIST, version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm. BRAFi-naïve were the participants with BRAF-mutation positive melanoma who had not received prior therapy with a BRAF-inhibitor..</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) in Part B BRAFi Naïve Melanoma Participants</measure>
    <time_frame>From the date of first dose until date of death due to any cause (up to approximately 22 months)</time_frame>
    <description>OS is defined as the interval of time between the date of randomization until the date of death due to any cause. For the participants who did not die, overall survival was censored at the date of last contact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre- and Post-dose H-scores for Individual Participants in Part B</measure>
    <time_frame>Screening and at disease progression (up to approximately 8 months)</time_frame>
    <description>p-ERK and p-AKT, biomarkers in tumor biopsies, were assessed for participants with BRAF mutant colorectal cancer. The H-score, which is a composite score that comprises intensity and percentage of staining, is a method of assessing the amount of protein or phospho-protein present in a biopsy sample. The score is obtained by the formula: (3 * percentage of strongly staining nuclei) + (2 * percentage of moderately staining nuclei) + (percentage of weakly staining nuclei). The H-score ranges from 0 to 300, with a score of 0 representing the absence of any of the target protein and an H-score of 300 representing maximum staining and intensity of the target protein.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) in Part C</measure>
    <time_frame>From the date of randomization until date of death due to any cause (up to approximately 17 months)</time_frame>
    <description>OS is defined as the interval of time between the date of randomization until the date of death due to any cause. For the participants who did not die, overall survival was censored at the date of last contact. When calculating overall survival, deaths following crossover were included.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of Dabrafenib and Its Metabolites in Part C</measure>
    <time_frame>Day 15, Week 8, Week 16, Week 24, Week 32, Week 40, Week 48, and Week 56</time_frame>
    <description>Plasma concentrations of dabrafenib and its metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) were assesed following daily dose of dabrafenib and trametinib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of Trametinib in Part C</measure>
    <time_frame>Day 15, Week 8, Week 16, Week 24, Week 32, Week 40, Week 48, and Week 56</time_frame>
    <description>Plasma concentrations of trametinib was assessed following daily dose of dabrafenib and trametinib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral Clearance (CL/F) of Dabrafenib and Trametinib</measure>
    <time_frame>Day 15, Week 8, Week 16, Week 24, Week 32, Week 40, and Week 48</time_frame>
    <description>Oral clearance (CL/F) of dabrafenib and trametinib were assessed using a population approach. Oral clearance (CL/F) is defined as the apparent volume of plasma in the vascular compartment cleared of drug per unit time by the processes of metabolism and excretion. For dabrafenib, population CL/F is defined as inducible and non-inducible CL/F. As dabrafenib induces its own metabolism, total oral clearance at steady state includes a non-induced (Day 1) component and an induced component, as estimated by a population PK model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral Volume of Distribution (V/F) of Dabrafenib and Trametinib</measure>
    <time_frame>Day 15, Week 8, Week 16, Week 24, Week 32, Week 40, and Week 48</time_frame>
    <description>Oral volume of distribution (V/F) of dabrafenib and trametinib were assessed using a population approach. Oral volume of distribution (V/F) is defined as the apparent volume of distribution in the central compartment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of Dabrafenib Metabolites in Part D</measure>
    <time_frame>Day 1: pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 24 hours post dose. Day 21: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 10 hours post-dose</time_frame>
    <description>The maximum concentration (Cmax) of dabrafenib metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) after single and repeat doses of DAB alone and in combination with trametinib was measured at Day 1 and Day 21.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Tmax of Dabrafenib Metabolites in Part D</measure>
    <time_frame>Day 1: pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 24 hours post dose. Day 21: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 10 hours post-dose</time_frame>
    <description>The time to Cmax (tmax) of DAB metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) after single and repeat doses of DAB alone and in combination with trametinib was measured at Day 1 and Day 21.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve (AUC) of Dabrafenib Metabolites in Part D</measure>
    <time_frame>Day 1: pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 24 hours post dose. Day 21: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 10 hours post-dose</time_frame>
    <description>Area under the concentration-time curve (AUC) from pre-dose to dosing interval (AUC[0-tau]), from pre-dose to the last time of quantifiable concentration (AUC[0-tau]), and from pre-dose extrapolated to infinity (AUC[0-inf]) of DAB metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) after single and repeat doses of DAB alone and in combination with trametinib was measured at Day 1 and Day 21.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Cmax Assessment of Trametinib in Part D</measure>
    <time_frame>Day 1: pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 24 hours post dose. Day 21: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 10 hours post-dose</time_frame>
    <description>Cmax of trametinib after single and repeat dose in combination with DAB was observed at Day 1 and Day 21. Blood samples for PK analysis of dabrafenib were obtained at pre-dose Day 1 and Day 21 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours (Day 1 only) post-dose administration. From the plasma concentration-time curve, the PK parameter tmax was determined by standard non-compartmental analysis using WinNonlin.Participants receiving DAB 75 mg to DAB 75 mg + Trametinib 2 mg and those receiving DAB 150 mg to DAB 150 mg + Trametinib 2 mg did not receive Trametinib until Day 29; therefore, Cmax was not analyzed in these participants at Days 1 and 21.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Tmax Assessment of Trametinib in Part D</measure>
    <time_frame>Day 1: pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 24 hours post dose. Day 21: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 10 hours post-dose</time_frame>
    <description>The tmax of trametinib after single and repeat dose in combination with dabrafenib (DAB) was observed at Day 1 and Day 21. Blood samples for PK analysis of dabrafenib were obtained at pre-dose Day 1 and Day 21 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours (Day 1 only) post-dose administration. From the plasma concentration-time curve, the PK parameter tmax was determined by standard non-compartmental analysis using WinNonlin.Participants receiving DAB 75 mg to DAB 75 mg + Trametinib 2 mg and those receiving DAB 150 mg to DAB 150 mg + Trametinib 2 mg did not receive Trametinib until Day 29; therefore, tmax was not analyzed in these participants at Days 1 and 21.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve Assessment of Trametinib in Part D</measure>
    <time_frame>Day 1: pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 24 hours post dose. Day 21: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 10 hours post-dose</time_frame>
    <description>AUC(0-tau) after single and repeat dose of trametinib alone and in combination with dabrafenib was observed at Day 1 and Day 21. Blood samples for PK analysis of dabrafenib were obtained at pre-dose Day 1 and Day 21 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours (Day 1 only) post-dose administration. From the plasma concentration-time curve, the PK parameter tmax was determined by standard non-compartmental analysis using WinNonlin.Participants receiving DAB 75 mg to DAB 75 mg + Trametinib 2 mg and those receiving DAB 150 mg to DAB 150 mg + Trametinib 2 mg did not receive Trametinib until Day 29; therefore, AUC(0-tau) was not analyzed in these participants at Days 1 and 21.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the Best Overall Response as Assessed by the Investigator in Participants in Part D</measure>
    <time_frame>From the date of first dose of study medication to the first documented evidence of a confirmed complete response or partial response (up to approximately 280 days )</time_frame>
    <description>Best overall response is defined as complete response (CR: the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 millimeter [mm] in the short axis.) or partial response (PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]). To be assigned a status of PR or CR, a confirmatory disease assessment should be performed no less than 28 days after the criteria for response are first met. Response was evaluated by an investigator as per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response as Assessed by the Investigator in Part D</measure>
    <time_frame>First documented evidence of PR or CR until the earlier of date of disease progression or date of death due to any cause (up to approximately 13 months)</time_frame>
    <description>Duration of response for participants with either a CR (the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 mm in the short axis.) or PR (at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]) is defined as the time from the first documented evidence of a PR or CR until the first documented sign of disease progression (PD) or death due to any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS) as Assessed by the Investigator in Part D</measure>
    <time_frame>From the date of randomization to the earliest date of disease progression (PD) or death due to any cause (up to approximately 13 months)</time_frame>
    <description>PFS is defined as the interval between the first dose of study medication and the earliest date of PD or death due to any cause. PD was based on radiographic or photographic evidence, and assessments were made by the investigator according to RECIST, version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival in Part D</measure>
    <time_frame>From the date of first dose until date of death due to any cause (up to approximately 14 months)</time_frame>
    <description>OS is defined as the interval of time between the date of randomization until the date of death due to any cause. For the participants who did not die, overall survival was censored at the date of last contact. Validation of OS is currently ongoing; thus, data are not available at this time.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">430</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Arm Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: GSK2118436 75mg; Day 2 through Day 16: GSK1120212 2mg; Day 15: GSK2118436 75mg +GSK1120212 2mg Drug-drug interaction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK2118436 + GSK1120212 Dose escalation to a maximum tolerated combination dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm Part C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK2118436 + GSK1120212 cohort expansion for safety and efficacy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2118436</intervention_name>
    <description>GSK2118436 is a potent and selective inhibitor of BRAF kinase activity with a mode of action consistent with adenosine triphosphate-competitive inhibition.</description>
    <arm_group_label>Arm Part C</arm_group_label>
    <arm_group_label>Arm Part B</arm_group_label>
    <arm_group_label>Arm Part A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK1120212</intervention_name>
    <description>GSK1120212 is a potent and highly selective inhibitor of MEK1/2 activation and kinase activity.</description>
    <arm_group_label>Arm Part C</arm_group_label>
    <arm_group_label>Arm Part A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Capable of given written informed consent, which includes compliance with the
             requirements and restrictions listed in the consent form.

          -  Male or female age 18 years or greater; able to swallow and retain oral medication.

          -  BRAF mutation positive melanoma or colorectal cancer; other BRAF mutation positive
             tumor types may be considered.

          -  Measurable disease according to RECIST version 1.1.

          -  Eastern Cooperative Oncology Group Performance Status of 0 or 1 for Parts A and B.
             Subjects with Eastern Cooperative Oncology Group Performance Status of 2 or less may
             be entered into Part C with approval of medical monitor.

          -  Agree to contraception requirements.

          -  Calcium phosphorus product less than 4.0mmol2/L2.

          -  Adequate organ system function.

        Exclusion Criteria:

          -  Currently receiving cancer therapy (chemotherapy, radiation therapy, immunotherapy, or
             biologic therapy).

          -  Part A and Part B: Prior exposure to BRAF or MEK inhibitors unless approved by the GSK
             Medical Monitor.

          -  Part C: Prior exposure to BRAF or MEK inhibitors. Prior anti-cancer therapy in the
             metastatic setting, with the exception of up to one regimen of chemotherapy and/or
             interleukin-2 (IL-2).

          -  Part D: Prior exposure to BRAF inhibitors. A washout period of 6 weeks is required for
             ipilimumab.

          -  Received an investigational anti-cancer drug within 4 weeks or 5 half-lives (whichever
             is shorter) of study drug administration--- at least 14 days must have passed between
             the last dose of prior investigational anti-cancer drug and the first dose of study
             drug.

          -  Current use of a prohibited medication or requires any of these medications during
             treatment with study drug.

          -  Current use of therapeutic warfarin.

          -  Any major surgery, radiotherapy, or immunotherapy within the last 4 weeks. Limited
             radiotherapy within the last 2 weeks.

          -  Chemotherapy regimens with delayed toxicity within the last 4 weeks. Chemotherapy
             regimens given continuously or on a weekly basis with limited potential for delayed
             toxicity within the last 2 weeks.

          -  Unresolved toxicity greater than National Cancer Institute-Common Terminology Criteria
             for Adverse Events version 4 Grade 1 from previous anti-cancer therapy except
             alopecia.

          -  History of retinal vein occlusion, central serous retinopathy or glaucoma.

          -  Predisposing factors to retinal vein occlusion including uncontrolled hypertension,
             uncontrolled diabetes, uncontrolled hyperlipidemia, and coagulopathy.

          -  Visible retinal pathology as assessed by ophthalmologic exam that is considered a risk
             factor for retinal vein occlusion or central serous retinopathy.

          -  Intraocular pressure greater than 21mm Hg as measured by tonography.

          -  Glaucoma diagnosed within one month prior to study Day 1.

          -  Presence of active gastrointestinal disease or other condition that will interfere
             significantly with the absorption, distribution, metabolism or excretion of drugs.

          -  Known human immunodeficiency virus, Hepatitis B or Hepatitis C infection.

          -  Primary malignancy of the central nervous system.

          -  Untreated or symptomatic brain metastasis, leptomeningeal disease or spinal cord
             compression. Subjects who are on a stable dose of corticosteroids for more than 1
             month or off corticosteroids for 2 weeks can be enrolled with approval of medical
             monitor. Subjects are not permitted to receive enzyme-inducing anti-epileptic drugs.

          -  Subjects with brain metastases are excluded, unless

             a. All known lesions must be previously treated with surgery or stereotactic
             radiosurgery, and- b. Brain lesion(s), if still present, must be confirmed stable
             (i.e. no increase in lesion size) for ≥90 days prior to first dose on study (must be
             documented with two consecutive MRI or CT scans using contrast), and c. Asymptomatic
             with no corticosteroids requirement for ≥ 30 days prior to first dose on study, and d.
             No enzyme-inducing anticonvulsants for ≥ 30 days prior to first dose on study.

          -  History of alcohol or drug abuse within 6 months prior to screening.

          -  Psychological, familial, sociological or geographical conditions that do not permit
             compliance with the protocol.

          -  QTc interval greater than or equal to 480msecs.

          -  History of acute coronary syndromes (including unstable angina), coronary angioplasty,
             or stenting within the past 24 weeks.

          -  Class II, III, or IV heart failure as defined by the New York Heart Association
             functional classification system.

          -  Abnormal cardiac valve morphology (subjects with minimal abnormalities can be entered
             on study with approval from the medical monitor.

          -  Treatment refractory hypertension defined as a blood pressure of systolic&gt; 140 mmHg
             and/or diastolic &gt; 90 mm Hg which cannot be controlled by anti-hypertensive therapy

          -  Patients with intra-cardiac defibrillators or permanent pacemakers.

          -  Cardiac metastases

          -  Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
             chemically related to the study drugs or excipients.

          -  Pregnant or lactating female.

          -  Unwillingness or inability to follow the procedures required in the protocol.

          -  Uncontrolled diabetes, hypertension or other medical conditions that may interfere
             with assessment of toxicity.

          -  Subjects with known glucose 6 phosphate dehydrogenase deficiency.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site</name>
      <address>
        <city>Lutherville-Timonium</city>
        <state>Maryland</state>
        <zip>21093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA 3rd, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012 Nov 1;367(18):1694-703. doi: 10.1056/NEJMoa1210093. Epub 2012 Sep 29.</citation>
    <PMID>23020132</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2010</study_first_submitted>
  <study_first_submitted_qc>February 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2010</study_first_posted>
  <results_first_submitted>June 27, 2013</results_first_submitted>
  <results_first_submitted_qc>September 19, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 21, 2013</results_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>drug-drug interaction</keyword>
  <keyword>BRAF inhibitor</keyword>
  <keyword>expansion cohorts</keyword>
  <keyword>melanoma</keyword>
  <keyword>dose escalation</keyword>
  <keyword>MEK inhibitor</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trametinib</mesh_term>
    <mesh_term>Dabrafenib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The study was comprised of Parts A, B, and D, which constitute the Phase I part of the study, and Part C, which constitutes the randomized Phase II part of the study. Participants did not enroll in all parts of the study sequentially. Each part of the study was comprised of a separate population of participants.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part A: Dabrafenib 75 mg + Trametinib 2 mg</title>
          <description>Participants received a single dose of dabrafenib 75 mg gelatin capsules with repeat dose trametinib (Day 15).</description>
        </group>
        <group group_id="P2">
          <title>Part B: Dabrafenib 75 mg + Trametinib 1 mg</title>
          <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 75 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available pharmacokinetic (PK), safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on dose-limiting toxicities (DLTs) occurring during the first 3 weeks of treatment.</description>
        </group>
        <group group_id="P3">
          <title>Part B: Dabrafenib 150 mg + Trametinib 1 mg</title>
          <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors and participants who had salivary ductal cancer received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
        </group>
        <group group_id="P4">
          <title>Part B: Dabrafenib 150 mg + Trametinib 1.5 mg</title>
          <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 150 mg gelatin capsules BID and trametinib 1.5 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
        </group>
        <group group_id="P5">
          <title>Part B: Dabrafenib 150 mg + Trametinib 2 mg</title>
          <description>Melanoma BRAF-positive participants who received prior treatment with BRAF inhibitors and participants who had colorectal cancer and BRAFi naïve melanoma received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD as continuous daily dosing. Dose escalation did not proceed beyond these doses of dabrafenib and trametinib.</description>
        </group>
        <group group_id="P6">
          <title>Part C (Randomized): Dabrafenib 150 mg</title>
          <description>Participants received dabrafenib 150 mg gelatin capsules BID.</description>
        </group>
        <group group_id="P7">
          <title>Part C (Randomized): Dabrafenib 150 mg + Trametinib 1 mg</title>
          <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD.</description>
        </group>
        <group group_id="P8">
          <title>Part C (Randomized): Dabrafenib 150 mg + Trametinib 2 mg</title>
          <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD.</description>
        </group>
        <group group_id="P9">
          <title>Part C (Crossover): Dabrafenib 150 mg + Trametinib 2 mg</title>
          <description>Participants who received dabrafenib 150 mg capsules BID alone in the Randomized Phase were given the opportunity to receive combination dosing of dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD upon disease progression with approval of the GlaxoSmithKline (GSK) Medical Monitor.</description>
        </group>
        <group group_id="P10">
          <title>Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg</title>
          <description>Participants received dabrafenib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
        </group>
        <group group_id="P11">
          <title>Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg</title>
          <description>Participants received dabrefinib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
        </group>
        <group group_id="P12">
          <title>Part D: Dabrafenib 75 mg + Trametinib 2 mg</title>
          <description>Participants received dabrafenib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
        </group>
        <group group_id="P13">
          <title>Part D: Dabrafenib 150 mg + Trametinib 2 mg</title>
          <description>Participants received dabrafenib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part A (Drug-Drug Interaction)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part B (Dose Escalation and Expansion)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="27"/>
                <participants group_id="P5" count="79"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Ongoing</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="28"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="27"/>
                <participants group_id="P5" count="79"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="36"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ongoing</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="28"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part C (Phase II: Randomized Phase)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="54"/>
                <participants group_id="P7" count="54"/>
                <participants group_id="P8" count="54"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Ongoing</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="35"/>
                <participants group_id="P7" count="32"/>
                <participants group_id="P8" count="40"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="54"/>
                <participants group_id="P7" count="54"/>
                <participants group_id="P8" count="54"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="19"/>
                <participants group_id="P7" count="18"/>
                <participants group_id="P8" count="14"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ongoing</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="35"/>
                <participants group_id="P7" count="32"/>
                <participants group_id="P8" count="40"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part C (Phase II: Crossover Phase [CP])</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="43"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Ongoing</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="28"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="43"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="15"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ongoing</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="28"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part D (HPMC Capsules)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="12"/>
                <participants group_id="P11" count="16"/>
                <participants group_id="P12" count="43"/>
                <participants group_id="P13" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Ongoing</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="10"/>
                <participants group_id="P11" count="12"/>
                <participants group_id="P12" count="34"/>
                <participants group_id="P13" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="12"/>
                <participants group_id="P11" count="16"/>
                <participants group_id="P12" count="43"/>
                <participants group_id="P13" count="39"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="2"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="4"/>
                <participants group_id="P12" count="6"/>
                <participants group_id="P13" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ongoing</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="10"/>
                <participants group_id="P11" count="12"/>
                <participants group_id="P12" count="34"/>
                <participants group_id="P13" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part A: Dabrafenib 75 mg + Trametinib 2 mg</title>
          <description>Participants received a single dose of dabrafenib 75 mg gelatin capsules with repeat dose trametinib (Day 15).</description>
        </group>
        <group group_id="B2">
          <title>Part B: Dabrafenib 75 mg + Trametinib 1 mg</title>
          <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 75 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available pharmacokinetic (PK), safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on dose-limiting toxicities (DLTs) occurring during the first 3 weeks of treatment.</description>
        </group>
        <group group_id="B3">
          <title>Part B: Dabrafenib 150 mg + Trametinib 1 mg</title>
          <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors and participants who had salivary ductal cancer received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
        </group>
        <group group_id="B4">
          <title>Part B: Dabrafenib 150 mg + Trametinib 1.5 mg</title>
          <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 150 mg gelatin capsules BID and trametinib 1.5 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
        </group>
        <group group_id="B5">
          <title>Part B: Dabrafenib 150 mg + Trametinib 2 mg</title>
          <description>Melanoma BRAF-positive participants who received prior treatment with BRAF inhibitors and participants who had colorectal cancer and BRAFi naïve melanoma received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD as continuous daily dosing. Dose escalation did not proceed beyond these doses of dabrafenib and trametinib.</description>
        </group>
        <group group_id="B6">
          <title>Part C: Dabrafenib 150 mg</title>
          <description>Participants received dabrafenib 150 mg gelatin capsules BID.</description>
        </group>
        <group group_id="B7">
          <title>Part C: Dabrafenib 150 mg + Trametinib 1 mg</title>
          <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD.</description>
        </group>
        <group group_id="B8">
          <title>Part C: Dabrafenib 150 mg + Trametinib 2 mg</title>
          <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD.</description>
        </group>
        <group group_id="B9">
          <title>Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg</title>
          <description>Participants received dabrafenib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
        </group>
        <group group_id="B10">
          <title>Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg</title>
          <description>Participants received dabrafenib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
        </group>
        <group group_id="B11">
          <title>Part D: Dabrafenib 75 mg + Trametinib 2 mg</title>
          <description>Participants received dabrafenib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
        </group>
        <group group_id="B12">
          <title>Part D: Dabrafenib 150 mg + Trametinib 2 mg</title>
          <description>Participants received dabrafenib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
        </group>
        <group group_id="B13">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="23"/>
            <count group_id="B4" value="27"/>
            <count group_id="B5" value="79"/>
            <count group_id="B6" value="54"/>
            <count group_id="B7" value="54"/>
            <count group_id="B8" value="54"/>
            <count group_id="B9" value="12"/>
            <count group_id="B10" value="16"/>
            <count group_id="B11" value="43"/>
            <count group_id="B12" value="39"/>
            <count group_id="B13" value="415"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.8" spread="16.04"/>
                    <measurement group_id="B2" value="48.2" spread="7.28"/>
                    <measurement group_id="B3" value="54.2" spread="13.24"/>
                    <measurement group_id="B4" value="52.2" spread="12.09"/>
                    <measurement group_id="B5" value="51.5" spread="12.82"/>
                    <measurement group_id="B6" value="51.8" spread="15.19"/>
                    <measurement group_id="B7" value="49.9" spread="14.70"/>
                    <measurement group_id="B8" value="55.9" spread="11.85"/>
                    <measurement group_id="B9" value="51.8" spread="12.39"/>
                    <measurement group_id="B10" value="53.1" spread="17.04"/>
                    <measurement group_id="B11" value="52.8" spread="14.57"/>
                    <measurement group_id="B12" value="56.7" spread="14.08"/>
                    <measurement group_id="B13" value="52.8" spread="13.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="44"/>
                    <measurement group_id="B6" value="25"/>
                    <measurement group_id="B7" value="24"/>
                    <measurement group_id="B8" value="20"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="8"/>
                    <measurement group_id="B11" value="18"/>
                    <measurement group_id="B12" value="14"/>
                    <measurement group_id="B13" value="185"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="35"/>
                    <measurement group_id="B6" value="29"/>
                    <measurement group_id="B7" value="30"/>
                    <measurement group_id="B8" value="34"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="8"/>
                    <measurement group_id="B11" value="25"/>
                    <measurement group_id="B12" value="25"/>
                    <measurement group_id="B13" value="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="77"/>
                    <measurement group_id="B6" value="52"/>
                    <measurement group_id="B7" value="54"/>
                    <measurement group_id="B8" value="53"/>
                    <measurement group_id="B9" value="12"/>
                    <measurement group_id="B10" value="16"/>
                    <measurement group_id="B11" value="43"/>
                    <measurement group_id="B12" value="39"/>
                    <measurement group_id="B13" value="407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian &amp; White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) of a Single Dose of Dabrafenib Administered Alone and in Combination With Trametinib in Part A</title>
        <description>Blood samples for PK analysis of dabrafenib and its the metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) were obtained at pre-dose and at 1, 2, 3, 4, 6, 8, 10, and 24 hours after dabrafenib administration. From the plasma concentration-time curve, the PK parameter Cmax was determined by standard non-compartmental analysis using WinNonlin. Cmax data are reported as geometric least squares means.</description>
        <time_frame>Day 15</time_frame>
        <population>Pharmacokinetic (PK) Population: all participants who received at least one dose of either dabrafenib or trametinib and for whom a PK sample was obtained and analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Dabrafenib 75 mg</title>
            <description>Participants received a single dose of dabrafenib 75 mg gelatin capsules alone on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Dabrafenib 75 mg + Trametinib 2 mg</title>
            <description>Participants received a single dose of dabrafenib 75 mg gelatin capsules with repeat dose trametinib (Day 15).</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of a Single Dose of Dabrafenib Administered Alone and in Combination With Trametinib in Part A</title>
          <description>Blood samples for PK analysis of dabrafenib and its the metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) were obtained at pre-dose and at 1, 2, 3, 4, 6, 8, 10, and 24 hours after dabrafenib administration. From the plasma concentration-time curve, the PK parameter Cmax was determined by standard non-compartmental analysis using WinNonlin. Cmax data are reported as geometric least squares means.</description>
          <population>Pharmacokinetic (PK) Population: all participants who received at least one dose of either dabrafenib or trametinib and for whom a PK sample was obtained and analyzed</population>
          <units>Nanograms per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GSK2118436</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="509" lower_limit="379" upper_limit="685"/>
                    <measurement group_id="O2" value="524" lower_limit="390" upper_limit="705"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2285403</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="259" lower_limit="190" upper_limit="352"/>
                    <measurement group_id="O2" value="255" lower_limit="196" upper_limit="331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2298683</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="724" lower_limit="595" upper_limit="879"/>
                    <measurement group_id="O2" value="747" lower_limit="587" upper_limit="951"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2167542</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.37" lower_limit="4.82" upper_limit="14.5"/>
                    <measurement group_id="O2" value="8.16" lower_limit="5.68" upper_limit="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Cmax of dabrafenib was log e transformed and analyzed by a linear mixed effect model with fixed effect for treatment (dabrafenib alone and combined with trametinib) and participant as a random effect. Geometric mean ratio (Day 15/Day 1) and 90% confidence interval were provided.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.34</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (Day 15 Cmax/Day 1 Cmax) and 90% confidence interval for dabrafenib were calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Cmax of GSK2285403 was log e transformed and analyzed by a linear mixed effect model with fixed effect for treatment (dabrafenib alone and combined with trametinib) and participant as a random effect. Geometric mean ratio (Day 15/Day 1) and 90% confidence interval were provided.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>.99</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (Day 15 Cmax/Day 1 Cmax) and 90% confidence interval for GSK2285403 were calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Cmax of GSK2298683 was log e transformed and analyzed by a linear mixed effect model with fixed effect for treatment (dabrafenib alone and combined with trametinib) and participant as a random effect. Geometric mean ratio (Day 15/Day 1) and 90% confidence interval were provided.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (Day 15 Cmax/Day 1 Cmax) and 90% confidence interval for GSK2298683 were calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Cmax of GSK2167542 was log e transformed and analyzed by a linear mixed effect model with fixed effect for treatment (dabrafenib alone and combined with trametinib) and participant as a random effect. Geometric mean ratio (Day 15/Day 1) and 90% confidence interval were provided.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>.98</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.45</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (Day 15 Cmax/Day 1 Cmax) and 90% confidence interval for GSK2167542 were calculated.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC (0-t) and AUC (0-inf) of Dabrafenib and Its Metabolites in Part A</title>
        <description>Blood samples for PK analysis of dabrafenib and its metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) were obtained at pre-dose and at 1, 2, 3, 4, 6, 8, 10, and 24 hours after dabrafenib administration. AUC is defined as the area under the dabrafenib concentration-time curve as a measure of drug exposure. AUC (0-inf) is defined as the area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time. AUC (0-t) is defined as area under the concentration-time curve from time zero (pre-dose) to the last time of quantifiable concentration. Date are reported as geometric least square means.</description>
        <time_frame>Day 15</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Dabrafenib 75 mg</title>
            <description>Participants received a single dose of dabrafenib 75 mg gelatin capsules alone on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Dabrafenib 75 mg + Trametinib 2 mg</title>
            <description>Participants received a single dose of dabrafenib 75 mg gelatin capsules with repeat dose trametinib (Day 15).</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0-t) and AUC (0-inf) of Dabrafenib and Its Metabolites in Part A</title>
          <description>Blood samples for PK analysis of dabrafenib and its metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) were obtained at pre-dose and at 1, 2, 3, 4, 6, 8, 10, and 24 hours after dabrafenib administration. AUC is defined as the area under the dabrafenib concentration-time curve as a measure of drug exposure. AUC (0-inf) is defined as the area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time. AUC (0-t) is defined as area under the concentration-time curve from time zero (pre-dose) to the last time of quantifiable concentration. Date are reported as geometric least square means.</description>
          <population>PK Population</population>
          <units>ng*hour/mL (ng*hr/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GSK2118436 AUC (0-t), n=8, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2734" lower_limit="2205" upper_limit="3390"/>
                    <measurement group_id="O2" value="2751" lower_limit="2219" upper_limit="3411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2118436 AUC (0-inf), n=7, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3128" lower_limit="2578" upper_limit="3797"/>
                    <measurement group_id="O2" value="2949" lower_limit="2445" upper_limit="3556"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2285403 AUC (0-t), n=8, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2232" lower_limit="1684" upper_limit="2959"/>
                    <measurement group_id="O2" value="2287" lower_limit="1899" upper_limit="2753"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2285403 AUC (0-inf), n=6, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2819" lower_limit="2231" upper_limit="3562"/>
                    <measurement group_id="O2" value="2497" lower_limit="2097" upper_limit="2974"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2298683 AUC (0-t), n=8, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12761" lower_limit="10347" upper_limit="15738"/>
                    <measurement group_id="O2" value="13053" lower_limit="10475" upper_limit="16266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2298683 AUC (0-inf), n=0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">PK parameter AUC(0-inf) could not be calculated in some participants.</measurement>
                    <measurement group_id="O2" value="NA">PK parameter AUC(0-inf) could not be calculated in some participants.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2167542 AUC (0-t), n=8, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="270" lower_limit="188" upper_limit="390"/>
                    <measurement group_id="O2" value="276" lower_limit="230" upper_limit="332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2167542 AUC (0-inf), n=8, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">PK parameter AUC(0-inf) could not be calculated in some participants.</measurement>
                    <measurement group_id="O2" value="NA">PK parameter AUC(0-inf) could not be calculated in some participants.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>AUC(0-t) of dabrafenib was log e transformed and analyzed by a linear mixed effect model with fixed effect for treatment (dabrafenib alone and combined with trametinib) and participant as a random effect. Geometric mean ratio (Day 15/Day 1) and 90% confidence interval were provided.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (Day 15 AUC(0-inf)/ Day 1 AUC(0-inf)) and 90% confidence interval for dabrafenib were calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>AUC(0-inf) of dabrafenib was log e transformed and analyzed by a linear mixed effect model with fixed effect for treatment (dabrafenib alone and combined with trametinib) and participant as a random effect. Geometric mean ratio (Day 15/Day 1) and 90% confidence interval were provided.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>0.94</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (Day 15 AUC(0-inf)/ Day 1 AUC(0-inf)) and 90% confidence interval for dabrafenib were calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>AUC(0-t) of GSK2285403 was log e transformed and analyzed by a linear mixed effect model with fixed effect for treatment (dabrafenib alone and combined with trametinib) and participant as a random effect. Geometric mean ratio (Day 15/Day 1) and 90% confidence interval were provided.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (Day 15 AUC(0-t)/ Day 1 AUC(0-t)) and 90% confidence interval for GSK2285403 were calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>AUC(0-inf) of GSK2285403 was log e transformed and analyzed by a linear mixed effect model with fixed effect for treatment (dabrafenib alone and combined with trametinib) and participant as a random effect. Geometric mean ratio (Day 15/Day 1) and 90% confidence interval were provided.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>0.92</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (Day 15 AUC(0-inf)/ Day 1 AUC(0-inf)) and 90% confidence interval for GSK2285403 were calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>AUC(0-t) of GSK2298683 was log e transformed and analyzed by a linear mixed effect model with fixed effect for treatment (dabrafenib alone and combined with trametinib) and participant as a random effect. Geometric mean ratio (Day 15/Day 1) and 90% confidence interval were provided.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (Day 15 AUC(0-t)/ Day 1 AUC(0-t)) and 90% confidence interval for GSK2298683 were calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>AUC(0-t) of GSK2167542 was log e transformed and analyzed by a linear mixed effect model with fixed effect for treatment (dabrafenib alone and combined with trametinib) and participant as a random effect. Geometric mean ratio (Day 15/Day 1) and 90% confidence interval were provided.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.37</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (Day 15 AUC(0-t)/ Day 1 AUC(0-t)) and 90% confidence interval for GSK2167542 were calculated.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) in Part B</title>
        <description>An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury. Refer to the general Adverse AE/SAE module for a complete list of AEs and SAEs.</description>
        <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 103 weeks )</time_frame>
        <population>All Treated Participants (ATP) Population: all participants who received at least one dose of either dabrafenib or trametinib</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Dabrafenib 75 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 75 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available pharmacokinetic (PK), safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on dose-limiting toxicities (DLTs) occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors and participants who had salivary ductal cancer received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1.5 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 150 mg gelatin capsules BID and trametinib 1.5 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Melanoma BRAF-positive participants who received prior treatment with BRAF inhibitors and participants who had colorectal cancer and BRAFi naïve melanoma received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD as continuous daily dosing. Dose escalation did not proceed beyond these doses of dabrafenib and trametinib.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) in Part B</title>
          <description>An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury. Refer to the general Adverse AE/SAE module for a complete list of AEs and SAEs.</description>
          <population>All Treated Participants (ATP) Population: all participants who received at least one dose of either dabrafenib or trametinib</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With the Indicated Worst-case Grade (G) Change From Baseline in the Indicated Clinical Chemistry Parameters in Part B</title>
        <description>Clinical chemistry parameters were summarized according to National Cancer Institutes (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred. For clinical chemistry parameters that were not graded according to NCI CTCAE criteria, changes above (High) and below (Low) the normal range were evaluated. Clinical chemistry parameters included: hyponatremia, gamma glutamyltransferase (GGT), phosphorous inorganic, alkaline phosphatase, hyperglycemia, aspartate aminotransferase (AST), hypokalemia, albumin, alanine aminotransferase (ALT), total bilirubin, hyperkalemia, hypoglycemia, creatinine, lactate dehydrogenase, urea/blood urea nitrogen (BUN), bicarbonate, chloride, creatine clearance, total protein, uric acid, and troponin T.</description>
        <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 103 weeks)</time_frame>
        <population>ATP Population. Only those participants who were available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Dabrafenib 75 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 75 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available pharmacokinetic (PK), safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on dose-limiting toxicities (DLTs) occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors and participants who had salivary ductal cancer received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1.5 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 150 mg gelatin capsules BID and trametinib 1.5 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Melanoma BRAF-positive participants who received prior treatment with BRAF inhibitors and participants who had colorectal cancer and BRAFi naïve melanoma received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD as continuous daily dosing. Dose escalation did not proceed beyond these doses of dabrafenib and trametinib.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Indicated Worst-case Grade (G) Change From Baseline in the Indicated Clinical Chemistry Parameters in Part B</title>
          <description>Clinical chemistry parameters were summarized according to National Cancer Institutes (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred. For clinical chemistry parameters that were not graded according to NCI CTCAE criteria, changes above (High) and below (Low) the normal range were evaluated. Clinical chemistry parameters included: hyponatremia, gamma glutamyltransferase (GGT), phosphorous inorganic, alkaline phosphatase, hyperglycemia, aspartate aminotransferase (AST), hypokalemia, albumin, alanine aminotransferase (ALT), total bilirubin, hyperkalemia, hypoglycemia, creatinine, lactate dehydrogenase, urea/blood urea nitrogen (BUN), bicarbonate, chloride, creatine clearance, total protein, uric acid, and troponin T.</description>
          <population>ATP Population. Only those participants who were available at the indicated time points were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hyponatremia, G3, n=6, 23, 27, 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT, G3, n=6, 23, 27, 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphorus, inorganic, G3, n=6, 23, 27, 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase, G3, n=6, 23, 27, 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperglycemia, G3, n=6, 23, 27, 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, G3, n=6, 23, 27, 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypokalemia, G3, n=6, 23, 27, 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, G3, n=6, 23, 27, 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, G3, n=6, 23, 27, 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin, G3, n=6, 23, 27, 77</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperkalemia, G3, n=6, 23, 27, 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoglycemia, G3, n=6, 23, 27, 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, G4, n=6, 23, 27, 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lactate dehydrogenase, High, n=6, 23, 27, 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN, High, n=6, 23, 27, 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate, High, n=6, 21, 26, 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, High, n=6, 23, 27, 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine clearance, High, n=5, 22, 24, 70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total protein, High, n=6, 23, 27, 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric acid, High, n=6, 23, 27, 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Troponin T, High, n=0, 0, 2, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, Low, n=6, 23, 27, 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total protein, Low, n=6, 23, 27, 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric acid, Low, n=6, 23, 27, 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine clearance, Low, n=5, 22, 24, 70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN, Low, n=6, 23, 27, 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate, Low, n=6, 21, 26, 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lactate dehydrogenase, Low, n=6, 23, 27, 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With the Indicated Worst-case Grade Change From Baseline in the Indicated Hematology Parameters in Part B</title>
        <description>Hematology parameters were summarized according to NCI CTCAE grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred. For hematology parameters that were not graded according to NCI CTCAE criteria, changes above (High) and below (Low) the normal range were evaluated. Hematology parameters included: lymphocytes decreased, total neutrophils, hemoglobin decreased, white blood cell counts, platelet counts, monocytes, mean corpuscular hemoglobin concentration (MCHC), eosinophils, basophils, mean corpuscular hemoglobin, mean corpuscular volume, red blood cell count, hematocrit, and reticulocytes.</description>
        <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 103 weeks)</time_frame>
        <population>ATP Population. Only those participants who were available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Dabrafenib 75 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 75 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available pharmacokinetic (PK), safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on dose-limiting toxicities (DLTs) occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors and participants who had salivary ductal cancer received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1.5 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 150 mg gelatin capsules BID and trametinib 1.5 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Melanoma BRAF-positive participants who received prior treatment with BRAF inhibitors and participants who had colorectal cancer and BRAFi naïve melanoma received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD as continuous daily dosing. Dose escalation did not proceed beyond these doses of dabrafenib and trametinib.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Indicated Worst-case Grade Change From Baseline in the Indicated Hematology Parameters in Part B</title>
          <description>Hematology parameters were summarized according to NCI CTCAE grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred. For hematology parameters that were not graded according to NCI CTCAE criteria, changes above (High) and below (Low) the normal range were evaluated. Hematology parameters included: lymphocytes decreased, total neutrophils, hemoglobin decreased, white blood cell counts, platelet counts, monocytes, mean corpuscular hemoglobin concentration (MCHC), eosinophils, basophils, mean corpuscular hemoglobin, mean corpuscular volume, red blood cell count, hematocrit, and reticulocytes.</description>
          <population>ATP Population. Only those participants who were available at the indicated time points were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lymphocytes decreased, G3, n=6, 23, 27, 79</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total neutrophils, G3, n=6, 23, 27, 79</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin decreased, G3, n=6, 23, 27, 79</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White blood cell count, G3, n=6, 23, 27, 79</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count, G3, n=6, 23, 27, 79</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes decreased, G4, n=6, 23, 27, 79</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count, G4, n=6, 23, 27, 79</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes, High, n=6, 23, 27, 79</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCHC, High, n=6, 23, 27, 79</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils, High, n=6, 23, 27, 79</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils, High, n=6, 23, 27, 79</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean corpuscle hemoglobin, High, n=6, 23, 27, 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean corpuscle volume, High, n=6, 23, 27, 79</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red blood cell count, High, n=6, 23, 27, 79</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit, High, n=6, 23, 27, 79</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reticulocytes, High, n=6, 17, 22, 27</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red blood cell count, Low, n=6, 23, 27, 79</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit, Low, n=6, 23, 27, 79</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes, Low, n=6, 23, 27, 79</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCHC, Low, n=6, 23, 27, 79</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean corpuscle volume, Low, n=6, 23, 27, 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean corpuscle hemoglobin, Low, n=6, 23, 27, 79</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils, Low, n=6, 23, 27, 79</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reticulocytes, Low, n=6, 17, 22, 27</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With the Indicated Worst-case Change From Baseline in Heart Rate and Blood Pressure in Part B</title>
        <description>Blood pressure and heart rate were summarized according to NCI CTCAE grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to G3 or G4 occurred. Blood pressure measurement included systolic blood pressure (SBP, millimeters of mercury [mmHg]) and diastolic BP (DBP). Heart rate is the measure of heart beats per minute (bpm). Changes in heart rate, either decrease to &lt;60 bpm, change to normal or no change, or increase to &gt;100 bpm are presented.</description>
        <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 103 weeks)</time_frame>
        <population>ATP Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Dabrafenib 75 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 75 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available pharmacokinetic (PK), safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on dose-limiting toxicities (DLTs) occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors and participants who had salivary ductal cancer received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1.5 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 150 mg gelatin capsules BID and trametinib 1.5 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Melanoma BRAF-positive participants who received prior treatment with BRAF inhibitors and participants who had colorectal cancer and BRAFi naïve melanoma received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD as continuous daily dosing. Dose escalation did not proceed beyond these doses of dabrafenib and trametinib.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Indicated Worst-case Change From Baseline in Heart Rate and Blood Pressure in Part B</title>
          <description>Blood pressure and heart rate were summarized according to NCI CTCAE grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to G3 or G4 occurred. Blood pressure measurement included systolic blood pressure (SBP, millimeters of mercury [mmHg]) and diastolic BP (DBP). Heart rate is the measure of heart beats per minute (bpm). Changes in heart rate, either decrease to &lt;60 bpm, change to normal or no change, or increase to &gt;100 bpm are presented.</description>
          <population>ATP Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Heart rate, Decrease to &lt;60 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate, Change to normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate, Increase to &gt;100 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Increase to G3 or G4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Increase to G3 or G4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With BRAF Mutant Metastatic Melanoma With Best Overall Response as Assessed by the Investigator in Part C (Randomized)</title>
        <description>Best overall response is defined as complete response (CR: the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 millimeters [mm] in the short axis.) or partial response (PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]). Participants with unknown or missing responses were considered as non-responders. To be assigned a status of PR or CR, a confirmatory disease assessment should have been performed no less than 28 days after the criteria for response were first met. Response was evaluated by an investigator as per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.</description>
        <time_frame>From the first dose of study medication to the first documented evidence of a confirmed complete response or partial response (up to approximately 47 weeks)</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants regardless of whether or not treatment was administered</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: Dabrafenib 150 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID.</description>
          </group>
          <group group_id="O2">
            <title>Part C: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD.</description>
          </group>
          <group group_id="O3">
            <title>Part C: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With BRAF Mutant Metastatic Melanoma With Best Overall Response as Assessed by the Investigator in Part C (Randomized)</title>
          <description>Best overall response is defined as complete response (CR: the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 millimeters [mm] in the short axis.) or partial response (PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]). Participants with unknown or missing responses were considered as non-responders. To be assigned a status of PR or CR, a confirmatory disease assessment should have been performed no less than 28 days after the criteria for response were first met. Response was evaluated by an investigator as per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants regardless of whether or not treatment was administered</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7730</p_value>
            <method>unconditional exact method</method>
            <param_type>Difference in response rate Arm2 - Arm1</param_type>
            <param_value>-4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.1</ci_lower_limit>
            <ci_upper_limit>15.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With BRAF Mutant Metastatic Melanoma With Best Overall Response Assessed by Blinded Independent Central Review (BICR) in Part C (Randomized)</title>
        <description>Best overall response is defined as complete response (CR: the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 mm in the short axis.) or partial response (PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]). Participants with unknown or missing responses were considered as non-responders. To be assigned a status of PR or CR, a confirmatory disease assessment should have been performed no less than 28 days after the criteria for response were first met. Response was evaluated by BICR as per RECIST, version 1.1.</description>
        <time_frame>From the first dose of study medication to the first documented evidence of a confirmed complete response or partial response (up to approximately 36 weeks)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: Dabrafenib 150 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID.</description>
          </group>
          <group group_id="O2">
            <title>Part C: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD.</description>
          </group>
          <group group_id="O3">
            <title>Part C: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With BRAF Mutant Metastatic Melanoma With Best Overall Response Assessed by Blinded Independent Central Review (BICR) in Part C (Randomized)</title>
          <description>Best overall response is defined as complete response (CR: the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 mm in the short axis.) or partial response (PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]). Participants with unknown or missing responses were considered as non-responders. To be assigned a status of PR or CR, a confirmatory disease assessment should have been performed no less than 28 days after the criteria for response were first met. Response was evaluated by BICR as per RECIST, version 1.1.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5008</p_value>
            <method>unconditional exact method</method>
            <param_type>Difference in response rate Arm2- Arm1</param_type>
            <param_value>-7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.7</ci_lower_limit>
            <ci_upper_limit>12.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1486</p_value>
            <method>unconditional exact method</method>
            <param_type>Difference in response rate Arm3 - Arm1</param_type>
            <param_value>15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.0</ci_lower_limit>
            <ci_upper_limit>33.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With BRAF Mutant Metastatic Melanoma With Best Overall Response as Assessed by the Investigator in Part C (Crossover)</title>
        <description>Best overall response is defined as complete response (CR: the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 mm in the short axis.) or partial response (PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]). Participants with unknown or missing responses were considered as non-responders. To be assigned a status of PR or CR, a confirmatory disease assessment should have been performed no less than 28 days after the criteria for response were first met. Response was evaluated by an investigator as per RECIST, version 1.1.</description>
        <time_frame>From the first dose of study medication to the first documented evidence of a confirmed complete response or partial response (up to approximately 15 weeks)</time_frame>
        <population>Crossover Population: participants who were randomized to and received at least one dose of dabrafenib monotherapy, and who elected to crossover to combination therapy following disease progression while on monotherapy</population>
        <group_list>
          <group group_id="O1">
            <title>Part C (Crossover): Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants who received dabrafenib 150 mg capsules BID alone in the Randomized Phase were given the opportunity to receive combination dosing of dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD upon disease progression with approval of the GlaxoSmithKline (GSK) Medical Monitor.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With BRAF Mutant Metastatic Melanoma With Best Overall Response as Assessed by the Investigator in Part C (Crossover)</title>
          <description>Best overall response is defined as complete response (CR: the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 mm in the short axis.) or partial response (PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]). Participants with unknown or missing responses were considered as non-responders. To be assigned a status of PR or CR, a confirmatory disease assessment should have been performed no less than 28 days after the criteria for response were first met. Response was evaluated by an investigator as per RECIST, version 1.1.</description>
          <population>Crossover Population: participants who were randomized to and received at least one dose of dabrafenib monotherapy, and who elected to crossover to combination therapy following disease progression while on monotherapy</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Response rate</param_type>
            <param_value>9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.6</ci_lower_limit>
            <ci_upper_limit>22.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Duration of Response as Assessed by the Investigator and Blinded Independent Central Review (BICR) in Part C (Randomized)</title>
        <description>Duration of response for participants with either a CR (the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 mm in the short axis.) or PR (at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]) is defined as the time from the first documented evidence of a PR or CR until the first documented sign of disease progression (PD) or death due to any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm.</description>
        <time_frame>First documented evidence of PR or CR until the date of the first documented sign of disease progression or the date of death due to any cause (up to approximately 17 months)</time_frame>
        <population>ITT Population. Only those participants who had a CR or PR were analyzed for duration of response.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: Dabrafenib 150 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID.</description>
          </group>
          <group group_id="O2">
            <title>Part C: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD.</description>
          </group>
          <group group_id="O3">
            <title>Part C: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response as Assessed by the Investigator and Blinded Independent Central Review (BICR) in Part C (Randomized)</title>
          <description>Duration of response for participants with either a CR (the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 mm in the short axis.) or PR (at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]) is defined as the time from the first documented evidence of a PR or CR until the first documented sign of disease progression (PD) or death due to any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm.</description>
          <population>ITT Population. Only those participants who had a CR or PR were analyzed for duration of response.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Investigator assessed, n=29, 27, 41</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="4.5" upper_limit="7.4"/>
                    <measurement group_id="O2" value="9.5" lower_limit="7.4">At the time of this report, the data was not yet mature; therefore, the upper limit (UL) of the CI could not be estimated.</measurement>
                    <measurement group_id="O3" value="10.5" lower_limit="7.4" upper_limit="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BICR assessed, n=25, 21, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" lower_limit="5.5">At the time of this report, the data was not yet mature; therefore, the upper limit (UL) of the CI could not be estimated.</measurement>
                    <measurement group_id="O2" value="11.3" lower_limit="6.2">At the time of this report, the data was not yet mature; therefore, the upper limit (UL) of the CI could not be estimated.</measurement>
                    <measurement group_id="O3" value="7.6" lower_limit="6.9">At the time of this report, the data was not yet mature; therefore, the upper limit (UL) of the CI could not be estimated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (PFS) as Assessed by the Investigator in Part C (Randomized)</title>
        <description>PFS is defined as the interval between the first dose of study medication and the earliest date of PD or death due to any cause. PD was based on radiographic or photographic evidence, and assessments were made by the investigator according to RECIST, version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm. Participants who received anti-cancer therapy prior to the date of documented events, were censored at the last adequate assessment prior to the initiation of therapy. If the participant did not had a documented date of events, PFS and survival were censored at the date of the last adequate assessment.</description>
        <time_frame>From the first dose of study medication to the earliest date of disease progression (PD) or death due to any cause (up to approximately 17 months)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: Dabrafenib 150 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID.</description>
          </group>
          <group group_id="O2">
            <title>Part C: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD.</description>
          </group>
          <group group_id="O3">
            <title>Part C: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS) as Assessed by the Investigator in Part C (Randomized)</title>
          <description>PFS is defined as the interval between the first dose of study medication and the earliest date of PD or death due to any cause. PD was based on radiographic or photographic evidence, and assessments were made by the investigator according to RECIST, version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm. Participants who received anti-cancer therapy prior to the date of documented events, were censored at the last adequate assessment prior to the initiation of therapy. If the participant did not had a documented date of events, PFS and survival were censored at the date of the last adequate assessment.</description>
          <population>ITT Population</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" lower_limit="4.6" upper_limit="7.4"/>
                    <measurement group_id="O2" value="9.2" lower_limit="6.4" upper_limit="11.0"/>
                    <measurement group_id="O3" value="9.4" lower_limit="8.6" upper_limit="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0057</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.37</ci_lower_limit>
            <ci_upper_limit>0.87</ci_upper_limit>
            <estimate_desc>HRs were estimated using the Pike estimator.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.25</ci_lower_limit>
            <ci_upper_limit>0.62</ci_upper_limit>
            <estimate_desc>HRs were estimated using the Pike estimator.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (PFS) as Assessed by the Blinded Independent Central Review (BICR) in Part C (Randomized)</title>
        <description>PFS is defined as the interval between the first dose of study medication and the earliest date of PD or death due to any cause. PD was based on radiographic or photographic evidence, and assessments were made by the BICR according to RECIST, version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm. Participants who received anti-cancer therapy prior to the date of documented events, were censored at the last adequate assessment prior to the initiation of therapy. If the participant did not had a documented date of events, PFS and survival were censored at the date of the last adequate assessment</description>
        <time_frame>From the first dose of study medication to the earliest date of disease progression (PD) or death due to any cause (up to approximately 17 months)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: Dabrafenib 150 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID.</description>
          </group>
          <group group_id="O2">
            <title>Part C: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD.</description>
          </group>
          <group group_id="O3">
            <title>Part C: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS) as Assessed by the Blinded Independent Central Review (BICR) in Part C (Randomized)</title>
          <description>PFS is defined as the interval between the first dose of study medication and the earliest date of PD or death due to any cause. PD was based on radiographic or photographic evidence, and assessments were made by the BICR according to RECIST, version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm. Participants who received anti-cancer therapy prior to the date of documented events, were censored at the last adequate assessment prior to the initiation of therapy. If the participant did not had a documented date of events, PFS and survival were censored at the date of the last adequate assessment</description>
          <population>ITT Population</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" lower_limit="5.5" upper_limit="9.4"/>
                    <measurement group_id="O2" value="8.3" lower_limit="5.6" upper_limit="11.3"/>
                    <measurement group_id="O3" value="9.2" lower_limit="7.6">At the time of this report, the data was not yet mature; therefore, t he upper limit (UL) of the CI could not be estimated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1721</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
            <estimate_desc>HRs were estimated using the Pike estimator.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0121</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.32</ci_lower_limit>
            <ci_upper_limit>0.91</ci_upper_limit>
            <estimate_desc>HRs were estimated using the Pike estimator.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (PFS) as Assessed by the Investigator in Part C (Crossover)</title>
        <description>PFS is defined as the interval between the first dose of study medication and the earliest date of PD or death due to any cause. PD was based on radiographic or photographic evidence, and assessments were made by the investigator according to RECIST, version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm. Participants received anti-cancer therapy prior to the date of documented events, and censored at the last adequate assessment, prior to the initiation of therapy. If the participant did not have a documented date of events, PFS and survival were censored at the date of the last adequate assessment.</description>
        <time_frame>From the first dose of study medication to the earliest date of disease progression (PD) or death due to any cause (up to approximately 9 months)</time_frame>
        <population>Crossover Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part C (Crossover): Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants who received dabrafenib 150 mg capsules BID alone in the Randomized Phase were given the opportunity to receive combination dosing of dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD upon disease progression with approval of the GlaxoSmithKline (GSK) Medical Monitor.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS) as Assessed by the Investigator in Part C (Crossover)</title>
          <description>PFS is defined as the interval between the first dose of study medication and the earliest date of PD or death due to any cause. PD was based on radiographic or photographic evidence, and assessments were made by the investigator according to RECIST, version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm. Participants received anti-cancer therapy prior to the date of documented events, and censored at the last adequate assessment, prior to the initiation of therapy. If the participant did not have a documented date of events, PFS and survival were censored at the date of the last adequate assessment.</description>
          <population>Crossover Population</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" lower_limit="1.8" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) in Part C (Randomized)</title>
        <description>An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury. Refer to the general Adverse AE/SAE module for a complete list of AEs and SAEs.</description>
        <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 75 weeks)</time_frame>
        <population>ATP Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: Dabrafenib 150 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID.</description>
          </group>
          <group group_id="O2">
            <title>Part C: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD.</description>
          </group>
          <group group_id="O3">
            <title>Part C: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) in Part C (Randomized)</title>
          <description>An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury. Refer to the general Adverse AE/SAE module for a complete list of AEs and SAEs.</description>
          <population>ATP Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With the Indicated Worst-case Grade (G) Change From Baseline in the Indicated Clinical Chemistry Parameters in Part C (Randomized)</title>
        <description>Clinical chemistry parameters were summarized according to National Cancer Institutes (NCI) CTCAE grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3, Severe; Grade 4, Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to any grade, Grade 3 or Grade 4 occurred. For clinical chemistry parameters that were not graded according to NCI CTCAE criteria, changes above (High) and below (Low) the normal range were evaluated. Clinical chemistry parameters included: albumin, alkaline phosphate (ALKP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total Bilirubin, calcium, creatine kinase, creatinine, gamma glutamyltransferase (GGT), glucose, potassium, magnesium, sodium, inorganic phosphorus. Worst case change from Baseline was calculated as the post-Baseline value minus the Baseline value.</description>
        <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 75 weeks)</time_frame>
        <population>ATP Population. Only those participants who were available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: Dabrafenib 150 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID.</description>
          </group>
          <group group_id="O2">
            <title>Part C: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD.</description>
          </group>
          <group group_id="O3">
            <title>Part C: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Indicated Worst-case Grade (G) Change From Baseline in the Indicated Clinical Chemistry Parameters in Part C (Randomized)</title>
          <description>Clinical chemistry parameters were summarized according to National Cancer Institutes (NCI) CTCAE grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3, Severe; Grade 4, Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to any grade, Grade 3 or Grade 4 occurred. For clinical chemistry parameters that were not graded according to NCI CTCAE criteria, changes above (High) and below (Low) the normal range were evaluated. Clinical chemistry parameters included: albumin, alkaline phosphate (ALKP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total Bilirubin, calcium, creatine kinase, creatinine, gamma glutamyltransferase (GGT), glucose, potassium, magnesium, sodium, inorganic phosphorus. Worst case change from Baseline was calculated as the post-Baseline value minus the Baseline value.</description>
          <population>ATP Population. Only those participants who were available at the indicated time points were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Albumin, any Grade, n=53, 54, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, G3, n=53, 54, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP, any Grade, n=53, 54, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALKP, G3, n=53, 54, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, any Grade, n=53, 54, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, G3, n=53, 54, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, any Grade, n=53, 54, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, G3, n=53, 54, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin, any Grade, n=53, 54, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin, G3, n=53, 54, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium (hypercalcemia), any Grade, n=53, 54, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium (hypercalcemia), G4, n=53, 54, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium (hypocalcemia), any Grade, n=53, 54, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine Kinase, any Grade, n=0, 0, 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Baseline grade and increase in grade of these participants was not available as no participants were analyzed.</measurement>
                    <measurement group_id="O2" value="NA">Baseline grade and increase in grade of these participants was not available as no participants were analyzed.</measurement>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, any Grade, n=53, 54, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, G3, n=53, 54, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, G4, n=53, 54, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT, any Grade, n=53, 54, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gamma glutamyltransferase, G3, n=53, 54, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose (hyperglycemia), any Grade, n=53, 54, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose (hyperglycemia), G3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose (hypoglycemia), any Grade, n=53, 54, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium (hyperkalemia), any Grade</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium (hyperkalemia), G3, n=53, 54, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium (hypokalemia), any Grade, n=53, 54, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium (hypokalemia), G3, n=53, 54, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium (hypokalemia), G4, n=53, 54, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnesium (hypermagnesemia), any Grade, n=53,53,55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnesium (hypermagnesemia), G3, n=53, 54, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnesium (hypomagnesemia), any Grade, n=53,53,55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnesium (hypomagnesemia), G3, n=53, 53, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium (hypernatremia), any Grade, n=53, 54, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium (hyponatremia), any Grade, n=53, 54, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium (hyponatremia), G3, n=53, 54, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphorus, inorganic, any Grade, n=53, 54, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphorus, inorganic, G3, n=53, 54, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With the Indicated Worst-case Grade Change From Baseline in the Indicated Hematology Parameters in Part C (Randomized)</title>
        <description>Hematology parameters were summarized according to National Cancer Institutes (NCI) CTCAE grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3, Severe; Grade 4, Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to any grade, Grade 3 or Grade 4 occurred. For hematology parameters that were not graded according to NCI CTCAE criteria, changes above (High) and below (Low) the normal range were evaluated. Hematology parameters included: hemoglobin, lymphocytes, Total absolute neutrophil count (ANC), platelet count, white blood cells (WBC) count. Worst case change from Baseline was calculated as the post-Baseline value minus the Baseline value.</description>
        <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 75 weeks)</time_frame>
        <population>ATP Population. Only those participants who were available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: Dabrafenib 150 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID.</description>
          </group>
          <group group_id="O2">
            <title>Part C: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD.</description>
          </group>
          <group group_id="O3">
            <title>Part C: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Indicated Worst-case Grade Change From Baseline in the Indicated Hematology Parameters in Part C (Randomized)</title>
          <description>Hematology parameters were summarized according to National Cancer Institutes (NCI) CTCAE grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3, Severe; Grade 4, Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to any grade, Grade 3 or Grade 4 occurred. For hematology parameters that were not graded according to NCI CTCAE criteria, changes above (High) and below (Low) the normal range were evaluated. Hematology parameters included: hemoglobin, lymphocytes, Total absolute neutrophil count (ANC), platelet count, white blood cells (WBC) count. Worst case change from Baseline was calculated as the post-Baseline value minus the Baseline value.</description>
          <population>ATP Population. Only those participants who were available at the indicated time points were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemoglobin (Increased), any Grade</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin (Anemia), any Grade</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin (Anemia), G3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (Increased), any Grade</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (Decreased), any Grade</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (Decreased), G3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (Decreased), G4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total ANC, any Grade</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total ANC, G3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total ANC, G4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count, any Grade</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count, G3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count, G4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC count, any Grade</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC count, G3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With the Indicated Worst-case Change From Baseline in Heart Rate and Blood Pressure in Part C (Randomized)</title>
        <description>Blood pressure were summarized according to National Cancer Institutes (NCI) CTCAE grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to G3 or G4 occurred.lood pressure measurement included systolic blood pressure (BP, millimeter of mercury [mmHg]) and diastolic BP (DBP). Worst case change from Baseline was calculated as the post-Baseline value minus the Baseline value. Heart Rate is the measure of heart beats per minute (bpm). Changes in heart rate, either decrease to &lt;60 bpm, change to normal or no change, or increase to &gt;100 bpm are presented.</description>
        <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 75 weeks)</time_frame>
        <population>ATP Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: Dabrafenib 150 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID.</description>
          </group>
          <group group_id="O2">
            <title>Part C: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD.</description>
          </group>
          <group group_id="O3">
            <title>Part C: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Indicated Worst-case Change From Baseline in Heart Rate and Blood Pressure in Part C (Randomized)</title>
          <description>Blood pressure were summarized according to National Cancer Institutes (NCI) CTCAE grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to G3 or G4 occurred.lood pressure measurement included systolic blood pressure (BP, millimeter of mercury [mmHg]) and diastolic BP (DBP). Worst case change from Baseline was calculated as the post-Baseline value minus the Baseline value. Heart Rate is the measure of heart beats per minute (bpm). Changes in heart rate, either decrease to &lt;60 bpm, change to normal or no change, or increase to &gt;100 bpm are presented.</description>
          <population>ATP Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic BP (mmHg) , G3 or G4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic BP (mmHg), G3 or G4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate, Decrease to &lt;60 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate, Change to normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate, Increase to &gt;100 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) of a Single and Repeat Dose of Dabrafenib Alone and in Combination With Trametinib in Part D (Analyte=GSK2118436)</title>
        <description>The PK parameter Cmax was assessed. Blood samples for PK analysis of dabrafenib were obtained at pre-dose Day 1 and Day 21 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours (24 hour on Day 1 only) post-dose administration. From the plasma concentration-time curve, the PK parameter tmax was determined by standard non-compartmental analysis using WinNonlin. Cmax data are reported as geometric least squares means.</description>
        <time_frame>Day 1 and Day 21</time_frame>
        <population>PK Population: all participants who received at least one dose of either dabrafenib or trametinib and for whom a PK sample was obtained and analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part D: Dabrafenib 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
          <group group_id="O4">
            <title>Part D: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of a Single and Repeat Dose of Dabrafenib Alone and in Combination With Trametinib in Part D (Analyte=GSK2118436)</title>
          <description>The PK parameter Cmax was assessed. Blood samples for PK analysis of dabrafenib were obtained at pre-dose Day 1 and Day 21 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours (24 hour on Day 1 only) post-dose administration. From the plasma concentration-time curve, the PK parameter tmax was determined by standard non-compartmental analysis using WinNonlin. Cmax data are reported as geometric least squares means.</description>
          <population>PK Population: all participants who received at least one dose of either dabrafenib or trametinib and for whom a PK sample was obtained and analyzed</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, n=15, 14, 15, 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1117" lower_limit="914" upper_limit="1365"/>
                    <measurement group_id="O2" value="1669" lower_limit="1059" upper_limit="2631"/>
                    <measurement group_id="O3" value="1227" lower_limit="924" upper_limit="1764"/>
                    <measurement group_id="O4" value="2289" lower_limit="1622" upper_limit="3231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21, n=14, 11, 14, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1050" lower_limit="811" upper_limit="1358"/>
                    <measurement group_id="O2" value="1746" lower_limit="1344" upper_limit="2269"/>
                    <measurement group_id="O3" value="1217" lower_limit="895" upper_limit="1654"/>
                    <measurement group_id="O4" value="2052" lower_limit="1472" upper_limit="2860"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Following loge tranformation, Cmax of dabrafenib after repeat doses from the pooled data in Part B and D were analyzed by a linear model with the following fixed effects as categorical variables: Capsule type (Gelatin or HPMC), BRAF dose (75 or 150 mg BID), Capsule type by BRAF dose interaction, Day (Day 15 or 21), MEK dose (0, 1, 1.5 or 2 mg QD). Geometric mean ratio (HPMC/Gelatin) and the corresponding 90% CI were provided for BRAF dose level 150 mg BID.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.51</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.10</ci_lower_limit>
            <ci_upper_limit>2.08</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (HPMC/Gelatin) and the corresponding 90% CI were provided for BRAF dose level 150 mg BID.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Tmax of a Single and Repeat Dose of Dabrafenib Alone and in Combination With Trametinib in Part D (Analyte=GSK2118436)</title>
        <description>tmax is defined as the time of occurence of Cmax. Blood samples for PK analysis of dabrafenib were obtained at Day 1 and Day 21 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 24 hours (24 hour on Day 1 only) post-dose administration. From the plasma concentration-time curve, the PK parameter tmax was determined by standard non-compartmental analysis using WinNonlin.</description>
        <time_frame>Day 1 and Day 21</time_frame>
        <population>PK Population. Only participants available at the indicated timepoints were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part D: Dabrafenib 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
          <group group_id="O4">
            <title>Part D: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>The Tmax of a Single and Repeat Dose of Dabrafenib Alone and in Combination With Trametinib in Part D (Analyte=GSK2118436)</title>
          <description>tmax is defined as the time of occurence of Cmax. Blood samples for PK analysis of dabrafenib were obtained at Day 1 and Day 21 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 24 hours (24 hour on Day 1 only) post-dose administration. From the plasma concentration-time curve, the PK parameter tmax was determined by standard non-compartmental analysis using WinNonlin.</description>
          <population>PK Population. Only participants available at the indicated timepoints were analyzed.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, n=15, 14, 15, 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O2" value="2.00" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O3" value="2.00" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O4" value="1.50" lower_limit="1.00" upper_limit="10.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21, n=14, 11, 14, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O2" value="1.55" lower_limit="0.98" upper_limit="3.00"/>
                    <measurement group_id="O3" value="1.75" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O4" value="1.50" lower_limit="1.00" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC (0-tau) and AUC (0-inf) of Single and Repeat Doses of Dabrafenib Alone and in Combination With Trametinib in Part D (Analyte=GSK2118436)</title>
        <description>The PK parameters were determined for area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration AUC (0-tau) and from time zero (pre-dose) extrapolated to infinite time AUC (0-inf). Blood samples for PK analysis of the metabolites of dabrafenib were obtained at Day 1 and Day 21 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours (24 hour only on Day 1) post-dose administration.</description>
        <time_frame>Day 1 and Day 21</time_frame>
        <population>PK Population. Only participants available at the indicated timepoints were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part D: Dabrafenib 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
          <group group_id="O4">
            <title>Part D: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0-tau) and AUC (0-inf) of Single and Repeat Doses of Dabrafenib Alone and in Combination With Trametinib in Part D (Analyte=GSK2118436)</title>
          <description>The PK parameters were determined for area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration AUC (0-tau) and from time zero (pre-dose) extrapolated to infinite time AUC (0-inf). Blood samples for PK analysis of the metabolites of dabrafenib were obtained at Day 1 and Day 21 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours (24 hour only on Day 1) post-dose administration.</description>
          <population>PK Population. Only participants available at the indicated timepoints were analyzed.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC (0-tau), Day 1, n=15, 13, 15, 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3593" lower_limit="3008" upper_limit="4293"/>
                    <measurement group_id="O2" value="6507" lower_limit="4288" upper_limit="9872"/>
                    <measurement group_id="O3" value="4618" lower_limit="3525" upper_limit="6051"/>
                    <measurement group_id="O4" value="7331" lower_limit="5355" upper_limit="10037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC (0-tau), Day 21, n=14, 11, 14, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3020" lower_limit="2390" upper_limit="3816"/>
                    <measurement group_id="O2" value="4663" lower_limit="3511" upper_limit="6194"/>
                    <measurement group_id="O3" value="3434" lower_limit="2679" upper_limit="4403"/>
                    <measurement group_id="O4" value="5886" lower_limit="4608" upper_limit="7517"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC (0-inf), Day 1, n=14, 13, 13, 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3982" lower_limit="3325" upper_limit="4770"/>
                    <measurement group_id="O2" value="7291" lower_limit="4830" upper_limit="11005"/>
                    <measurement group_id="O3" value="5321" lower_limit="4192" upper_limit="6755"/>
                    <measurement group_id="O4" value="8152" lower_limit="5860" upper_limit="11341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC (0-inf), Day 21, n=14, 11, 14, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">AUC(0-inf) is not applicable to Day 21.</measurement>
                    <measurement group_id="O2" value="NA">AUC(0-inf) is not applicable to Day 21.</measurement>
                    <measurement group_id="O3" value="NA">AUC(0-inf) is not applicable to Day 21.</measurement>
                    <measurement group_id="O4" value="NA">AUC(0-inf) is not applicable to Day 21.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Following log transformation, AUC(0-tau) of dabrafenib was analyzed by a linear mixed effect model with dosing chort and day as fixed effects and subject as random effect. Based on the model, geometric mean ratio (Day 21 Dabrafenib 150 mg BID+Trametinib 2 mg QD/Day 21 Dabrafenib 150 mg BID alone) and the corresponding 90% confidence interval were provided.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.23</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.69</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (Day 21 Dabrafenib 150 mg BID+Trametinib 2 mg QD/Day 21 Dabrafenib 150 mg BID alone) and the corresponding 90% confidence interval were provided.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Following loge tranformation, AUC(0-tau) of dabrafenib after repeat doses from the pooled data in Part B and D were analyzed by a linear model with the following fixed effects as categorical variables: Capsule type (Gelatin or HPMC), BRAF dose (75 or 150 mg BID), Capsule type by BRAF dose interaction, Day (Day 15 or 21), MEK dose (0, 1, 1.5, 2 or 2 mg QD). Geometric mean ratio (HPMC/Gelatin) and the corresponding 90% CI were then provided for BRAF dose level 150 mg BID.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.10</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.44</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (HPMC/Gelatin) and the corresponding 90% CI were provided for BRAF dose level 150 mg BID.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) in Part D</title>
        <description>An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event for possible drug-induced liver injury. Refer to the general Adverse AE/SAE module for a complete list of AEs and SAEs.</description>
        <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 61 weeks)</time_frame>
        <population>ATP Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part D: Dabrafenib 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
          <group group_id="O4">
            <title>Part D: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) in Part D</title>
          <description>An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event for possible drug-induced liver injury. Refer to the general Adverse AE/SAE module for a complete list of AEs and SAEs.</description>
          <population>ATP Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With the Indicated Worst-case Grade (G) Change From Baseline in the Indicated Clinical Chemistry Parameters in Part D</title>
        <description>Clinical chemistry parameters were summarized according to NCI CTCAE grade, version 4.0. G1, Mild; G2, Moderate; G3, Severe; G4, Life-threatening or disabling; G5, Death. Data are presented for only those parameters for which an increase to G3 or G4 occurred. Changes above (High) and below (Low) the normal range were evaluated for parameters not graded. Included:hyponatremia,gamma glutamyltransferase (GGT),aspartate aminotransferase (AST),hyperglycemia,alkaline phosphatase,hypokalemia,alanine aminotransferase (ALT),phosphorus inorganic,creatine kinase,total bilirubin,albumin,hyperkalemia, hypomagnesemia,lipase,hypokalemia,hyponatremia,urea/blood urea nitrogen (BUN),bicarbonate,creatine clearance,chloride,C-reactive protein,total protein,uric acid,troponin I,direct bilirubin,creatine kinase MB mass, chloride,total protein,bicarbonate,uric acid,creatine clearance,lactate dehydrogenase. Worst case change from BL was calculated as the post-BL value minus the BL value.</description>
        <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 61 weeks)</time_frame>
        <population>ATP Population. Only those participants available at indicated timepoints were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part D: Dabrafenib 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
          <group group_id="O4">
            <title>Part D: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Indicated Worst-case Grade (G) Change From Baseline in the Indicated Clinical Chemistry Parameters in Part D</title>
          <description>Clinical chemistry parameters were summarized according to NCI CTCAE grade, version 4.0. G1, Mild; G2, Moderate; G3, Severe; G4, Life-threatening or disabling; G5, Death. Data are presented for only those parameters for which an increase to G3 or G4 occurred. Changes above (High) and below (Low) the normal range were evaluated for parameters not graded. Included:hyponatremia,gamma glutamyltransferase (GGT),aspartate aminotransferase (AST),hyperglycemia,alkaline phosphatase,hypokalemia,alanine aminotransferase (ALT),phosphorus inorganic,creatine kinase,total bilirubin,albumin,hyperkalemia, hypomagnesemia,lipase,hypokalemia,hyponatremia,urea/blood urea nitrogen (BUN),bicarbonate,creatine clearance,chloride,C-reactive protein,total protein,uric acid,troponin I,direct bilirubin,creatine kinase MB mass, chloride,total protein,bicarbonate,uric acid,creatine clearance,lactate dehydrogenase. Worst case change from BL was calculated as the post-BL value minus the BL value.</description>
          <population>ATP Population. Only those participants available at indicated timepoints were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hyponatremia, G3, n=15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gamma glutamyltransferase, G3, n=15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, G3, n= 15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperglycemia, G3, n=15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase, G3, n=15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypokalemia, G3, n=15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, G3, n=15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphorus, inorganic, G3, n=15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine kinase, G3, n=2, 1, 4, 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin, G3, n=15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, G3, n=15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperkalemia, G3, n=15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypomagnesemia, G3, n=15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase, G4, n=15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gamma glutamyltransferase, G4, n=15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypokalemia, G4, n=15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyponatremia, G4, n=15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lactate dehydrogenase, High, n=15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN, High, n=15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate, High, n=15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine clearance, High, n=2, 1, 11 ,6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, High,n=15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C-reactive protein, High, n=2, 3, 2 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total protein, High, n=15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric acid, High, n=15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Troponin I, High, n=15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct bilirubin, High, n=15, 1, 1, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine kinaseMB mass,change to high,n=15,15,1,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, Low, n=15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total protein, Low, n=15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate, Low, n=15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric acid, Low, n=15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN, Low, n=15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine clearance, Low, n=4, 3, 3, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lactate dehydrogenase, Low, n=15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With the Indicated Worst-case Grade Change From Baseline in the Indicated Hematology Parameters in Part D</title>
        <description>Hematology parameters were summarized according to NCI CTCAE grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred. For hematology parameters that were not graded according to NCI CTCAE criteria, changes above (High) and below (Low) the normal range were evaluated. Hematology parameters included lymphocytes, total neutrophils, hemoglobin, white blood cell count, platelet count, monocytes, mean corpuscle hemoglobin concentration, eosinophils, basophils, mean corpuscle hemoglobin, mean corpuscle volume, red blood cell count, hematocrit, erythrocyte sedimentation, reticulocytes. Worst case change from Baseline was calculated as the post-Baseline value minus the Baseline value.</description>
        <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 61 weeks)</time_frame>
        <population>ATP Population. Only those participants available at indicated timepoints were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part D: Dabrafenib 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
          <group group_id="O4">
            <title>Part D: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Indicated Worst-case Grade Change From Baseline in the Indicated Hematology Parameters in Part D</title>
          <description>Hematology parameters were summarized according to NCI CTCAE grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred. For hematology parameters that were not graded according to NCI CTCAE criteria, changes above (High) and below (Low) the normal range were evaluated. Hematology parameters included lymphocytes, total neutrophils, hemoglobin, white blood cell count, platelet count, monocytes, mean corpuscle hemoglobin concentration, eosinophils, basophils, mean corpuscle hemoglobin, mean corpuscle volume, red blood cell count, hematocrit, erythrocyte sedimentation, reticulocytes. Worst case change from Baseline was calculated as the post-Baseline value minus the Baseline value.</description>
          <population>ATP Population. Only those participants available at indicated timepoints were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lymphocytes decreased, G3, n= 15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total neutrophils, G3, n= 15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin (Hb) decreased, G3, n= 15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White blood cell count, G3, n= 15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count, G3, n= 15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes decreased, G4, n= 15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count, G4, n= 15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes, G4, n= 15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean corpuscle Hb concentration High,n=15,15,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils, High, n= 15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils, High, n= 15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean corpuscle Hb, High, n= 15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean corpuscle volume, High, n= 15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red blood cell count, High, n= 15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit, High, n= 15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythrocyte sedimentation, High, n= 15, 15, 40, 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reticulocytes, High, n= 15, 15, 4, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red blood cell count, Low, n= 15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit, Low, n= 15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes, Low, n= 15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean corpuscle Hb concentration Low, n=15,15,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean corpuscle volume, Low, n= 15, 15, 41, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean corpuscle Hb, Low, n= 15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils, Low, n= 15, 15, 41, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reticulocytes, Low, n= 15, 15, 4, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils, Low, n= 15, 15, 40, 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With the Indicated Worst-case Change From Baseline in Heart Rate and Blood Pressure in Part D</title>
        <description>Blood pressure were summarized according to National Cancer Institutes (NCI) CTCAE grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to G3 or G4 occurred.lood pressure measurement included systolic blood pressure (BP, millimeter of mercury [mmHg]) and diastolic BP (DBP). Worst case change from Baseline was calculated as the post-Baseline value minus the Baseline value. Heart Rate is the measure of heartbeats per minute (bpm). Changes in heart rate, either decrease to &lt;60 bpm, change to normal or no change, or increase to &gt;100 bpm are presented</description>
        <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 61 weeks)</time_frame>
        <population>ATP Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part D: Dabrafenib 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
          <group group_id="O4">
            <title>Part D: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Indicated Worst-case Change From Baseline in Heart Rate and Blood Pressure in Part D</title>
          <description>Blood pressure were summarized according to National Cancer Institutes (NCI) CTCAE grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to G3 or G4 occurred.lood pressure measurement included systolic blood pressure (BP, millimeter of mercury [mmHg]) and diastolic BP (DBP). Worst case change from Baseline was calculated as the post-Baseline value minus the Baseline value. Heart Rate is the measure of heartbeats per minute (bpm). Changes in heart rate, either decrease to &lt;60 bpm, change to normal or no change, or increase to &gt;100 bpm are presented</description>
          <population>ATP Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Heart rate, Decrease to &lt;60 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate, Change to normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate, Increase to &gt;100 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic BP (mmHg) , increase to G3 or G4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic BP (mmHg), increase to G3 or G4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Steady State Concentration of Trametinib With Concomitant Administration of Dabrafenib in Part A</title>
        <description>The steady state plasma concentration (Css) of trametinib with concomitant dabrafenib administration was assessed at Day 15 and Day 16. At steady state the amount of drug administered (in a given time period) is equal to the amount of drug eliminated.</description>
        <time_frame>Day 15 and Day 16</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Dabrafenib 75 mg + Trametinib 2 mg</title>
            <description>Participants received a single dose of dabrafenib 75 mg gelatin capsules with repeat dose trametinib (Day 15).</description>
          </group>
        </group_list>
        <measure>
          <title>Steady State Concentration of Trametinib With Concomitant Administration of Dabrafenib in Part A</title>
          <description>The steady state plasma concentration (Css) of trametinib with concomitant dabrafenib administration was assessed at Day 15 and Day 16. At steady state the amount of drug administered (in a given time period) is equal to the amount of drug eliminated.</description>
          <population>PK Population</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" lower_limit="6" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" lower_limit="6" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The AUC [0-tau] of Dabrafenib (DAB) and Its Metabolite in Combination With Trametinib (T) in Part B</title>
        <description>Area under the concentration-time curve from time zero (predose) until the last time of quantifiable concentration (AUC [0-tau]) was assessed. Blood samples for PK analysis of dabrafenib and its the metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) were obtained at Day 15 pre-dose and Day 21 pre-dose and at 1, 2, 4, 6, and 8 hours post-dose administration.</description>
        <time_frame>Day 15 and Day 21</time_frame>
        <population>PK Population. Only those participants who were available at the indicated time point were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Dabrafenib 75 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 75 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available pharmacokinetic (PK), safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on dose-limiting toxicities (DLTs) occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors and participants who had salivary ductal cancer received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1.5 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 150 mg gelatin capsules BID and trametinib 1.5 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Melanoma BRAF-positive participants who received prior treatment with BRAF inhibitors and participants who had colorectal cancer and BRAFi naïve melanoma received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD as continuous daily dosing. Dose escalation did not proceed beyond these doses of dabrafenib and trametinib.</description>
          </group>
        </group_list>
        <measure>
          <title>The AUC [0-tau] of Dabrafenib (DAB) and Its Metabolite in Combination With Trametinib (T) in Part B</title>
          <description>Area under the concentration-time curve from time zero (predose) until the last time of quantifiable concentration (AUC [0-tau]) was assessed. Blood samples for PK analysis of dabrafenib and its the metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) were obtained at Day 15 pre-dose and Day 21 pre-dose and at 1, 2, 4, 6, and 8 hours post-dose administration.</description>
          <population>PK Population. Only those participants who were available at the indicated time point were analyzed.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DAB, Day 15, n=6, 4, 5, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2466" lower_limit="1458" upper_limit="4171"/>
                    <measurement group_id="O2" value="3539" lower_limit="1634" upper_limit="7666"/>
                    <measurement group_id="O3" value="5187" lower_limit="3737" upper_limit="7199"/>
                    <measurement group_id="O4" value="4114" lower_limit="1560" upper_limit="10848"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAB, Day 21, n=0, 8, 12, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O2" value="4656" lower_limit="3901" upper_limit="5557"/>
                    <measurement group_id="O3" value="4528" lower_limit="3602" upper_limit="5692"/>
                    <measurement group_id="O4" value="5518" lower_limit="3732" upper_limit="8158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2285403, Day 15, n=6, 4, 5, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2120" lower_limit="1366" upper_limit="3290"/>
                    <measurement group_id="O2" value="2163" lower_limit="1267" upper_limit="3694"/>
                    <measurement group_id="O3" value="3136" lower_limit="2501" upper_limit="3932"/>
                    <measurement group_id="O4" value="3180" lower_limit="1389" upper_limit="7283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2285403, Day 21, n=0, 8, 12, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O2" value="3257" lower_limit="2162" upper_limit="4907"/>
                    <measurement group_id="O3" value="2989" lower_limit="2545" upper_limit="3510"/>
                    <measurement group_id="O4" value="3632" lower_limit="2364" upper_limit="5581"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2298683, Day 15, n=6, 4, 5, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37159" lower_limit="22389" upper_limit="61673"/>
                    <measurement group_id="O2" value="40634" lower_limit="30329" upper_limit="54441"/>
                    <measurement group_id="O3" value="43727" lower_limit="31486" upper_limit="60727"/>
                    <measurement group_id="O4" value="68528" lower_limit="42444" upper_limit="110642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2298683 , Day 21, n=0, 8, 12, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O2" value="47911" lower_limit="30643" upper_limit="74909"/>
                    <measurement group_id="O3" value="49939" lower_limit="39219" upper_limit="63589"/>
                    <measurement group_id="O4" value="59965" lower_limit="45117" upper_limit="79699"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2167542, Day 15, n=6, 4, 5, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2859" lower_limit="1568" upper_limit="5216"/>
                    <measurement group_id="O2" value="2961" lower_limit="1206" upper_limit="7270"/>
                    <measurement group_id="O3" value="4156" lower_limit="2802" upper_limit="6165"/>
                    <measurement group_id="O4" value="3746" lower_limit="1992" upper_limit="7043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2167542, Day 21, n=0, 8, 12, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O2" value="3609" lower_limit="2279" upper_limit="5714"/>
                    <measurement group_id="O3" value="2995" lower_limit="1891" upper_limit="4743"/>
                    <measurement group_id="O4" value="3961" lower_limit="2361" upper_limit="6645"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-dose (Trough) Concentration at the End of the Dosing Interval (Ctau) and Maximum Plasma Concentration (Cmax) of Dabrafenib and Its Metabolite in Combination With Trametinib in Part B</title>
        <description>Pre-dose (trough) concentration at the end of the dosing interval (Ctau) and maximum plasma concentration (Cmax) were assessed for plasma dabrafenib (DAB) following repeat dosing of DAB administered in combination with trametinib (T). The trough concentration is defined as the plasma level of a pharmaceutical product measured just before the next dose. Blood samples for PK analysis of the metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) of dabrafenib were obtained at Day 15 pre-dose and Day 21 pre-dose and at 1, 2, 4, 6, and 8 hours post-dose administration.</description>
        <time_frame>Day 15 and Day 21</time_frame>
        <population>PK Population. Only those participants who were available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Dabrafenib 75 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 75 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available pharmacokinetic (PK), safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on dose-limiting toxicities (DLTs) occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors and participants who had salivary ductal cancer received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1.5 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 150 mg gelatin capsules BID and trametinib 1.5 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Melanoma BRAF-positive participants who received prior treatment with BRAF inhibitors and participants who had colorectal cancer and BRAFi naïve melanoma received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD as continuous daily dosing. Dose escalation did not proceed beyond these doses of dabrafenib and trametinib.</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-dose (Trough) Concentration at the End of the Dosing Interval (Ctau) and Maximum Plasma Concentration (Cmax) of Dabrafenib and Its Metabolite in Combination With Trametinib in Part B</title>
          <description>Pre-dose (trough) concentration at the end of the dosing interval (Ctau) and maximum plasma concentration (Cmax) were assessed for plasma dabrafenib (DAB) following repeat dosing of DAB administered in combination with trametinib (T). The trough concentration is defined as the plasma level of a pharmaceutical product measured just before the next dose. Blood samples for PK analysis of the metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) of dabrafenib were obtained at Day 15 pre-dose and Day 21 pre-dose and at 1, 2, 4, 6, and 8 hours post-dose administration.</description>
          <population>PK Population. Only those participants who were available at the indicated time points were analyzed.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DAB Ctau, Day 15, n=6, 4, 5, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.8" lower_limit="19.1" upper_limit="187"/>
                    <measurement group_id="O2" value="44.6" lower_limit="17.1" upper_limit="117"/>
                    <measurement group_id="O3" value="115" lower_limit="27.8" upper_limit="472"/>
                    <measurement group_id="O4" value="73.7" lower_limit="10.3" upper_limit="528"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAB Ctau, Day 21, n=0, 8, 12, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O2" value="185" lower_limit="79.7" upper_limit="428"/>
                    <measurement group_id="O3" value="102" lower_limit="57.1" upper_limit="184"/>
                    <measurement group_id="O4" value="79.9" lower_limit="32.2" upper_limit="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAB Cmax, Day 15, n=6, 4, 5, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="640" lower_limit="390" upper_limit="1048"/>
                    <measurement group_id="O2" value="906" lower_limit="221" upper_limit="3717"/>
                    <measurement group_id="O3" value="1306" lower_limit="700" upper_limit="2437"/>
                    <measurement group_id="O4" value="1046" lower_limit="545" upper_limit="2011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAB Cmax, Day 21, n=0, 8, 12, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O2" value="1263" lower_limit="863" upper_limit="1848"/>
                    <measurement group_id="O3" value="1346" lower_limit="997" upper_limit="1817"/>
                    <measurement group_id="O4" value="1391" lower_limit="1002" upper_limit="1932"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2285403 Ctau, Day 15, n=6, 4, 5, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.9" lower_limit="25.2" upper_limit="211"/>
                    <measurement group_id="O2" value="47.8" lower_limit="20.2" upper_limit="113"/>
                    <measurement group_id="O3" value="97.9" lower_limit="32.2" upper_limit="297"/>
                    <measurement group_id="O4" value="74.4" lower_limit="15.7" upper_limit="353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2285403 Ctau, Day 21, n=0, 8, 12, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O2" value="136" lower_limit="62.4" upper_limit="299"/>
                    <measurement group_id="O3" value="92.9" lower_limit="60.2" upper_limit="143"/>
                    <measurement group_id="O4" value="82.7" lower_limit="37.6" upper_limit="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2285403 Cmax, Day 15, n=6, 4, 5, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="399" lower_limit="265" upper_limit="601"/>
                    <measurement group_id="O2" value="418" lower_limit="146" upper_limit="1201"/>
                    <measurement group_id="O3" value="597" lower_limit="300" upper_limit="1186"/>
                    <measurement group_id="O4" value="630" lower_limit="411" upper_limit="964"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2285403 Cmax, Day 21, n=0, 8, 12, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O2" value="775" lower_limit="441" upper_limit="1364"/>
                    <measurement group_id="O3" value="668" lower_limit="507" upper_limit="882"/>
                    <measurement group_id="O4" value="722" lower_limit="502" upper_limit="1039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2298683 Ctau, Day 15, n=6, 4, 5, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2345" lower_limit="1237" upper_limit="4447"/>
                    <measurement group_id="O2" value="2360" lower_limit="1134" upper_limit="4911"/>
                    <measurement group_id="O3" value="2792" lower_limit="2069" upper_limit="3768"/>
                    <measurement group_id="O4" value="4372" lower_limit="2589" upper_limit="7384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2298683 Ctau, Day 21, n=0, 8, 12, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O2" value="2920" lower_limit="1674" upper_limit="5095"/>
                    <measurement group_id="O3" value="3221" lower_limit="2619" upper_limit="3962"/>
                    <measurement group_id="O4" value="3740" lower_limit="2564" upper_limit="5455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2298683 Cmax, Day 15, n=6, 4, 5, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3757" lower_limit="2385" upper_limit="5916"/>
                    <measurement group_id="O2" value="4545" lower_limit="3817" upper_limit="5411"/>
                    <measurement group_id="O3" value="4636" lower_limit="3258" upper_limit="6598"/>
                    <measurement group_id="O4" value="7098" lower_limit="4914" upper_limit="10254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2298683 Cmax, Day 21, n=0, 8, 12, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O2" value="5301" lower_limit="3392" upper_limit="8286"/>
                    <measurement group_id="O3" value="5416" lower_limit="4163" upper_limit="7048"/>
                    <measurement group_id="O4" value="6257" lower_limit="4937" upper_limit="7931"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2167542 Ctau, Day 15, n=6, 4, 5, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="257" lower_limit="140" upper_limit="473"/>
                    <measurement group_id="O2" value="249" lower_limit="79.4" upper_limit="782"/>
                    <measurement group_id="O3" value="331" lower_limit="185" upper_limit="590"/>
                    <measurement group_id="O4" value="318" lower_limit="260" upper_limit="389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2167542 Ctau, Day 21, n=0, 8, 12, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O2" value="196" lower_limit="90.8" upper_limit="425"/>
                    <measurement group_id="O3" value="248" lower_limit="140" upper_limit="439"/>
                    <measurement group_id="O4" value="369" lower_limit="191" upper_limit="714"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2167542 Cmax, Day 15, n=6, 4, 5, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="300" lower_limit="157" upper_limit="572"/>
                    <measurement group_id="O2" value="355" lower_limit="114" upper_limit="1108"/>
                    <measurement group_id="O3" value="523" lower_limit="251" upper_limit="1091"/>
                    <measurement group_id="O4" value="460" lower_limit="190" upper_limit="1113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2167542 Cmax, Day 21, n=0, 8, 12, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O2" value="543" lower_limit="298" upper_limit="989"/>
                    <measurement group_id="O3" value="373" lower_limit="248" upper_limit="562"/>
                    <measurement group_id="O4" value="430" lower_limit="226" upper_limit="818"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Tmax of Dabrafenib and Its Metabolite in Combination With Trametinib in Part B</title>
        <description>The tmax is defined as the time of occurence of Cmax. Tha tmax was assessed for plasma dabrafenib (DAB) following repeat dosing of dabrafenib 75 and 150 mg BID administered in combination with trametinib. Blood samples for PK analysis of the metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) of dabrafenib were obtained at Day 15 pre-dose and Day 21 pre-dose and at 1, 2, 4, 6, and 8 hours post-dose administration.</description>
        <time_frame>Day 15 and Day 21</time_frame>
        <population>PK Population. Only those participants who were available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Dabrafenib 75 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 75 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available pharmacokinetic (PK), safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on dose-limiting toxicities (DLTs) occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors and participants who had salivary ductal cancer received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1.5 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 150 mg gelatin capsules BID and trametinib 1.5 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Melanoma BRAF-positive participants who received prior treatment with BRAF inhibitors and participants who had colorectal cancer and BRAFi naïve melanoma received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD as continuous daily dosing. Dose escalation did not proceed beyond these doses of dabrafenib and trametinib.</description>
          </group>
        </group_list>
        <measure>
          <title>The Tmax of Dabrafenib and Its Metabolite in Combination With Trametinib in Part B</title>
          <description>The tmax is defined as the time of occurence of Cmax. Tha tmax was assessed for plasma dabrafenib (DAB) following repeat dosing of dabrafenib 75 and 150 mg BID administered in combination with trametinib. Blood samples for PK analysis of the metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) of dabrafenib were obtained at Day 15 pre-dose and Day 21 pre-dose and at 1, 2, 4, 6, and 8 hours post-dose administration.</description>
          <population>PK Population. Only those participants who were available at the indicated time points were analyzed.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DAB Day 15, n=6, 4, 5, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.03" upper_limit="2.00"/>
                    <measurement group_id="O2" value="2.00" lower_limit="1.03" upper_limit="6.00"/>
                    <measurement group_id="O3" value="2.00" lower_limit="1.00" upper_limit="2.10"/>
                    <measurement group_id="O4" value="1.50" lower_limit="1.00" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAB Day 21, n=0, 8, 12, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O2" value="1.54" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O3" value="1.53" lower_limit="1.00" upper_limit="2.03"/>
                    <measurement group_id="O4" value="2.04" lower_limit="1.00" upper_limit="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2285403 Day 15, n=6, 4, 5, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="2.00" upper_limit="2.03"/>
                    <measurement group_id="O2" value="2.00" lower_limit="1.03" upper_limit="8.00"/>
                    <measurement group_id="O3" value="2.00" lower_limit="2.00" upper_limit="4.03"/>
                    <measurement group_id="O4" value="2.00" lower_limit="2.00" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2285403 Day 21, n=0, 8, 12, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O2" value="1.97" lower_limit="0.00" upper_limit="2.00"/>
                    <measurement group_id="O3" value="2.00" lower_limit="1.00" upper_limit="2.03"/>
                    <measurement group_id="O4" value="2.07" lower_limit="1.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2298683 Day 15, n=6, 4, 5, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.00" lower_limit="4.00" upper_limit="8.00"/>
                    <measurement group_id="O2" value="4.96" lower_limit="0.00" upper_limit="6.30"/>
                    <measurement group_id="O3" value="4.17" lower_limit="1.00" upper_limit="8.02"/>
                    <measurement group_id="O4" value="4.10" lower_limit="4.00" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2298683 Day 21, n=0, 8, 12, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O2" value="4.00" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O3" value="4.00" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O4" value="4.02" lower_limit="2.00" upper_limit="8.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2167542 Day 15, n=6, 4, 5, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="4.17"/>
                    <measurement group_id="O2" value="2.94" lower_limit="0.00" upper_limit="8.00"/>
                    <measurement group_id="O3" value="4.17" lower_limit="1.00" upper_limit="8.02"/>
                    <measurement group_id="O4" value="1.52" lower_limit="0.00" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2167542 Day 21, n=0, 8, 12, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O2" value="2.00" lower_limit="1.00" upper_limit="2.32"/>
                    <measurement group_id="O3" value="1.01" lower_limit="0.00" upper_limit="8.00"/>
                    <measurement group_id="O4" value="1.50" lower_limit="0.00" upper_limit="8.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The AUC (0-tau) Assessment of Trametinib in Combination With Dabrafenib in Part B (Analyte=GSK1120212)</title>
        <description>AUC (0-tau) is defined as area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration. AUC (0-tau) was assessed for plasma trametinib following repeat dosing of trametinib in combination with dabrafenib. Blood samples for PK analysis of the metabolites of dabrafenib were obtained at Day 15 pre-dose and Day 21 pre-dose and at 1, 2, 4, 6, and 8 hours post-dose administration.</description>
        <time_frame>Day 15 and Day 21</time_frame>
        <population>PK Population. Only those participants who were available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Dabrafenib 75 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 75 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available pharmacokinetic (PK), safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on dose-limiting toxicities (DLTs) occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors and participants who had salivary ductal cancer received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1.5 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 150 mg gelatin capsules BID and trametinib 1.5 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Melanoma BRAF-positive participants who received prior treatment with BRAF inhibitors and participants who had colorectal cancer and BRAFi naïve melanoma received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD as continuous daily dosing. Dose escalation did not proceed beyond these doses of dabrafenib and trametinib.</description>
          </group>
        </group_list>
        <measure>
          <title>The AUC (0-tau) Assessment of Trametinib in Combination With Dabrafenib in Part B (Analyte=GSK1120212)</title>
          <description>AUC (0-tau) is defined as area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration. AUC (0-tau) was assessed for plasma trametinib following repeat dosing of trametinib in combination with dabrafenib. Blood samples for PK analysis of the metabolites of dabrafenib were obtained at Day 15 pre-dose and Day 21 pre-dose and at 1, 2, 4, 6, and 8 hours post-dose administration.</description>
          <population>PK Population. Only those participants who were available at the indicated time points were analyzed.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15, n=6, 4, 5, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169" lower_limit="113" upper_limit="252"/>
                    <measurement group_id="O2" value="147" lower_limit="101" upper_limit="212"/>
                    <measurement group_id="O3" value="217" lower_limit="139" upper_limit="338"/>
                    <measurement group_id="O4" value="394" lower_limit="229" upper_limit="679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21, n=0, 8, 12, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O2" value="169" lower_limit="146" upper_limit="194"/>
                    <measurement group_id="O3" value="269" lower_limit="238" upper_limit="304"/>
                    <measurement group_id="O4" value="351" lower_limit="284" upper_limit="432"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Ctau and Cmax Assessments of Trametinib in Combination With Dabrafenib in Part B (Analyte=GSK1120212)</title>
        <description>Pre-dose (trough) concentration at the end of the dosing interval (Ctau) and maximum plasma concentration (Cmax) were assessed for plasma trametinib following repeat dosing of trametinib in combination with dabrafenib. Blood samples for PK analysis of the metabolites of dabrafenib were obtained at Day 15 pre-dose or Day 21 pre-dose and at 1, 2, 4, 6, and 8 hours post-dose administration.</description>
        <time_frame>Day 15 and Day 21</time_frame>
        <population>PK Population. Only those participants who were available at the indicated time point were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Dabrafenib 75 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 75 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available pharmacokinetic (PK), safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on dose-limiting toxicities (DLTs) occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors and participants who had salivary ductal cancer received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1.5 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 150 mg gelatin capsules BID and trametinib 1.5 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Melanoma BRAF-positive participants who received prior treatment with BRAF inhibitors and participants who had colorectal cancer and BRAFi naïve melanoma received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD as continuous daily dosing. Dose escalation did not proceed beyond these doses of dabrafenib and trametinib.</description>
          </group>
        </group_list>
        <measure>
          <title>The Ctau and Cmax Assessments of Trametinib in Combination With Dabrafenib in Part B (Analyte=GSK1120212)</title>
          <description>Pre-dose (trough) concentration at the end of the dosing interval (Ctau) and maximum plasma concentration (Cmax) were assessed for plasma trametinib following repeat dosing of trametinib in combination with dabrafenib. Blood samples for PK analysis of the metabolites of dabrafenib were obtained at Day 15 pre-dose or Day 21 pre-dose and at 1, 2, 4, 6, and 8 hours post-dose administration.</description>
          <population>PK Population. Only those participants who were available at the indicated time point were analyzed.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ctau, Day 15, n=6, 4, 5, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.56" lower_limit="3.74" upper_limit="8.28"/>
                    <measurement group_id="O2" value="5.05" lower_limit="3.81" upper_limit="6.69"/>
                    <measurement group_id="O3" value="7.62" lower_limit="5.38" upper_limit="10.8"/>
                    <measurement group_id="O4" value="12.4" lower_limit="6.50" upper_limit="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ctau, Day 21, n=0, 8, 12, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O2" value="5.57" lower_limit="4.80" upper_limit="6.45"/>
                    <measurement group_id="O3" value="8.51" lower_limit="7.65" upper_limit="9.48"/>
                    <measurement group_id="O4" value="10.8" lower_limit="8.75" upper_limit="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax, Day 15, n=6, 4, 5, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" lower_limit="7.18" upper_limit="14.4"/>
                    <measurement group_id="O2" value="8.08" lower_limit="5.06" upper_limit="12.9"/>
                    <measurement group_id="O3" value="11.5" lower_limit="6.16" upper_limit="21.5"/>
                    <measurement group_id="O4" value="22.4" lower_limit="14.0" upper_limit="35.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax, Day 21, n=0, 8, 12, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O2" value="10.2" lower_limit="8.50" upper_limit="12.1"/>
                    <measurement group_id="O3" value="18.0" lower_limit="14.9" upper_limit="21.7"/>
                    <measurement group_id="O4" value="22.6" lower_limit="18.1" upper_limit="28.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Tmax Assessment of Trametinib in Combination With Dabrafenib in Part B (Analyte=GSK1120212)</title>
        <description>The tmax is defined as the time of occurrence of Cmax. The PK parameter for tmax was assessed for plasma trametinib following repeat dosing of trametinib in combination with dabrafenib. Blood samples for PK analysis of the metabolites of dabrafenib were obtained at Day 15 pre-dose or Day 21 pre-dose and at 1, 2, 4, 6, and 8 hours post-dose administration.</description>
        <time_frame>Day 15 and Day 21</time_frame>
        <population>PK Population. Only those participants who were available at the indicated time point were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Dabrafenib 75 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 75 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available pharmacokinetic (PK), safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on dose-limiting toxicities (DLTs) occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors and participants who had salivary ductal cancer received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1.5 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 150 mg gelatin capsules BID and trametinib 1.5 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Melanoma BRAF-positive participants who received prior treatment with BRAF inhibitors and participants who had colorectal cancer and BRAFi naïve melanoma received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD as continuous daily dosing. Dose escalation did not proceed beyond these doses of dabrafenib and trametinib.</description>
          </group>
        </group_list>
        <measure>
          <title>The Tmax Assessment of Trametinib in Combination With Dabrafenib in Part B (Analyte=GSK1120212)</title>
          <description>The tmax is defined as the time of occurrence of Cmax. The PK parameter for tmax was assessed for plasma trametinib following repeat dosing of trametinib in combination with dabrafenib. Blood samples for PK analysis of the metabolites of dabrafenib were obtained at Day 15 pre-dose or Day 21 pre-dose and at 1, 2, 4, 6, and 8 hours post-dose administration.</description>
          <population>PK Population. Only those participants who were available at the indicated time point were analyzed.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15, n=6, 4, 5, 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.03" upper_limit="4.00"/>
                    <measurement group_id="O2" value="2.00" lower_limit="1.00" upper_limit="8.00"/>
                    <measurement group_id="O3" value="2.00" lower_limit="1.00" upper_limit="8.00"/>
                    <measurement group_id="O4" value="1.52" lower_limit="1.00" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21, n=0, 8, 12, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants were analyzed in this treatment arm at this time point.</measurement>
                    <measurement group_id="O2" value="2.00" lower_limit="0.93" upper_limit="8.00"/>
                    <measurement group_id="O3" value="2.00" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O4" value="2.00" lower_limit="1.00" upper_limit="8.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With BRAFi-naïve Mutant Metastatic Melanoma With the Best Overall Response as Assessed by Investigator in Part B</title>
        <description>Best overall response is defined as complete response (CR: the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 millimeter [mm] in the short axis.) or partial response (PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]). Participants with unknown or missing response were considered as non-responders. To be assigned a status of PR or CR, a confirmatory disease assessment should have been performed no less than 28 days after the criteria for response were first met. Response was evaluated by an investigator as per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. BRAFi-naïve participants were those with BRAF-mutation-positive melanoma who had not received prior therapy with a BRAF inhibitor.</description>
        <time_frame>From the first dose of study medication to the first documented evidence of a confirmed complete response or partial response (up to 103 weeks)</time_frame>
        <population>All Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Dabrafenib 75 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 75 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available pharmacokinetic (PK), safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on dose-limiting toxicities (DLTs) occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors and participants who had salivary ductal cancer received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1.5 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 150 mg gelatin capsules BID and trametinib 1.5 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Melanoma BRAF-positive participants who received prior treatment with BRAF inhibitors and participants who had colorectal cancer and BRAFi naïve melanoma received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD as continuous daily dosing. Dose escalation did not proceed beyond these doses of dabrafenib and trametinib.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With BRAFi-naïve Mutant Metastatic Melanoma With the Best Overall Response as Assessed by Investigator in Part B</title>
          <description>Best overall response is defined as complete response (CR: the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 millimeter [mm] in the short axis.) or partial response (PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]). Participants with unknown or missing response were considered as non-responders. To be assigned a status of PR or CR, a confirmatory disease assessment should have been performed no less than 28 days after the criteria for response were first met. Response was evaluated by an investigator as per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. BRAFi-naïve participants were those with BRAF-mutation-positive melanoma who had not received prior therapy with a BRAF inhibitor.</description>
          <population>All Treated Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response as Assessed by the Investigator in Participants With BRAFi-naïve Mutant Metastatic Melanoma in Part B</title>
        <description>Duration of response for participants with either a CR (the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 mm in the short axis.) or PR (at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]) is defined as the time from the first documented evidence of a PR or CR until the first documented sign of disease progression (PD) or death due to any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm. BRAFi-naïve participants were those with BRAF-mutation-positive melanoma who had not received prior therapy with a BRAF inhibitor.</description>
        <time_frame>First documented evidence of PR or CR until the earlier of date of disease progression or date of death due to any cause (up to approximately 22 months)</time_frame>
        <population>All Treated Population. Only those participants who had a CR or PR were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Dabrafenib 75 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 75 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available pharmacokinetic (PK), safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on dose-limiting toxicities (DLTs) occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors and participants who had salivary ductal cancer received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1.5 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 150 mg gelatin capsules BID and trametinib 1.5 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Melanoma BRAF-positive participants who received prior treatment with BRAF inhibitors and participants who had colorectal cancer and BRAFi naïve melanoma received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD as continuous daily dosing. Dose escalation did not proceed beyond these doses of dabrafenib and trametinib.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response as Assessed by the Investigator in Participants With BRAFi-naïve Mutant Metastatic Melanoma in Part B</title>
          <description>Duration of response for participants with either a CR (the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 mm in the short axis.) or PR (at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]) is defined as the time from the first documented evidence of a PR or CR until the first documented sign of disease progression (PD) or death due to any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm. BRAFi-naïve participants were those with BRAF-mutation-positive melanoma who had not received prior therapy with a BRAF inhibitor.</description>
          <population>All Treated Population. Only those participants who had a CR or PR were analyzed.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" lower_limit="3.7" upper_limit="14.9"/>
                    <measurement group_id="O2" value="8.4" lower_limit="5.5">At the time of this report, the data was not yet mature; therefore, the upper limit (UL) of the CI could not be estimated.</measurement>
                    <measurement group_id="O3" value="12.6" lower_limit="6.5">At the time of this report, the data was not yet mature; therefore, the upper limit (UL) of the CI could not be estimated.</measurement>
                    <measurement group_id="O4" value="11.3" lower_limit="9.1" upper_limit="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS) as Assessed by the Investigator in Participants With BRAFi-naïve Mutant Metastatic Melanoma in Part B</title>
        <description>PFS is defined as the interval between the first dose of study medication and the earliest date of PD or death due to any cause. PD was based on radiographic or photographic evidence, and assessments were made by the investigator according to RECIST, version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm. BRAFi-naïve were the participants with BRAF-mutation positive melanoma who had not received prior therapy with a BRAF-inhibitor..</description>
        <time_frame>From the date of first dose to the earliest date of disease progression (PD) or death due to any cause (up to approximately 22 months)</time_frame>
        <population>All Treated Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Dabrafenib 75 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 75 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available pharmacokinetic (PK), safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on dose-limiting toxicities (DLTs) occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors and participants who had salivary ductal cancer received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1.5 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 150 mg gelatin capsules BID and trametinib 1.5 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Melanoma BRAF-positive participants who received prior treatment with BRAF inhibitors and participants who had colorectal cancer and BRAFi naïve melanoma received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD as continuous daily dosing. Dose escalation did not proceed beyond these doses of dabrafenib and trametinib.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS) as Assessed by the Investigator in Participants With BRAFi-naïve Mutant Metastatic Melanoma in Part B</title>
          <description>PFS is defined as the interval between the first dose of study medication and the earliest date of PD or death due to any cause. PD was based on radiographic or photographic evidence, and assessments were made by the investigator according to RECIST, version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm. BRAFi-naïve were the participants with BRAF-mutation positive melanoma who had not received prior therapy with a BRAF-inhibitor..</description>
          <population>All Treated Population.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" lower_limit="5.3" upper_limit="16.6"/>
                    <measurement group_id="O2" value="8.2" lower_limit="5.4" upper_limit="11.0"/>
                    <measurement group_id="O3" value="5.4" lower_limit="3.5" upper_limit="12.8"/>
                    <measurement group_id="O4" value="10.8" lower_limit="5.3" upper_limit="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) in Part B BRAFi Naïve Melanoma Participants</title>
        <description>OS is defined as the interval of time between the date of randomization until the date of death due to any cause. For the participants who did not die, overall survival was censored at the date of last contact.</description>
        <time_frame>From the date of first dose until date of death due to any cause (up to approximately 22 months)</time_frame>
        <population>All Treated Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Dabrafenib 75 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 75 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available pharmacokinetic (PK), safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on dose-limiting toxicities (DLTs) occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors and participants who had salivary ductal cancer received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1.5 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 150 mg gelatin capsules BID and trametinib 1.5 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Melanoma BRAF-positive participants who received prior treatment with BRAF inhibitors and participants who had colorectal cancer and BRAFi naïve melanoma received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD as continuous daily dosing. Dose escalation did not proceed beyond these doses of dabrafenib and trametinib.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) in Part B BRAFi Naïve Melanoma Participants</title>
          <description>OS is defined as the interval of time between the date of randomization until the date of death due to any cause. For the participants who did not die, overall survival was censored at the date of last contact.</description>
          <population>All Treated Population.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4" lower_limit="8.0">At the time of this report, the data was not yet mature; therefore, the upper limit (UL) of the CI could not be estimated.</measurement>
                    <measurement group_id="O2" value="16.4" lower_limit="14.5">At the time of this report, the data was not yet mature; therefore, the upper limit (UL) of the CI could not be estimated.</measurement>
                    <measurement group_id="O3" value="13.3" lower_limit="6.3">At the time of this report, the data was not yet mature; therefore, the upper limit (UL) of the CI could not be estimated.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="12.9">At the time of this report, the data was not yet mature; therefore, the median and the upper limit (UL) of the CI could not be estimated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre- and Post-dose H-scores for Individual Participants in Part B</title>
        <description>p-ERK and p-AKT, biomarkers in tumor biopsies, were assessed for participants with BRAF mutant colorectal cancer. The H-score, which is a composite score that comprises intensity and percentage of staining, is a method of assessing the amount of protein or phospho-protein present in a biopsy sample. The score is obtained by the formula: (3 * percentage of strongly staining nuclei) + (2 * percentage of moderately staining nuclei) + (percentage of weakly staining nuclei). The H-score ranges from 0 to 300, with a score of 0 representing the absence of any of the target protein and an H-score of 300 representing maximum staining and intensity of the target protein.</description>
        <time_frame>Screening and at disease progression (up to approximately 8 months)</time_frame>
        <population>Biomarker Population: participants with H-score data for pre- and post-biopsy pairs</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Dabrafenib + Trametinib</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib (75 mg or 150 mg) gelatin capsules BID and trametinib (1 mg, 1.5 mg, or 2 mg) tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available pharmacokinetic (PK), safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on dose-limiting toxicities (DLTs) occurring during the first 3 weeks of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Pre- and Post-dose H-scores for Individual Participants in Part B</title>
          <description>p-ERK and p-AKT, biomarkers in tumor biopsies, were assessed for participants with BRAF mutant colorectal cancer. The H-score, which is a composite score that comprises intensity and percentage of staining, is a method of assessing the amount of protein or phospho-protein present in a biopsy sample. The score is obtained by the formula: (3 * percentage of strongly staining nuclei) + (2 * percentage of moderately staining nuclei) + (percentage of weakly staining nuclei). The H-score ranges from 0 to 300, with a score of 0 representing the absence of any of the target protein and an H-score of 300 representing maximum staining and intensity of the target protein.</description>
          <population>Biomarker Population: participants with H-score data for pre- and post-biopsy pairs</population>
          <units>scores on a scale</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>p-ERK: Participant 1, pre-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-ERK: Participant 1, post-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-ERK: Participant 2, pre-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-ERK: Participant 2, post-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-ERK: Participant 3, pre-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-ERK: Participant 3, post-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-ERK: Participant 4, pre-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-ERK: Participant 4, post-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-ERK: Participant 5, pre-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-ERK: Participant 5, post-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-ERK: Participant 6, pre-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-ERK: Participant 6, post-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-ERK: Participant 7, pre-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-ERK: Participant 7, post-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-ERK: Participant 8, pre-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-ERK: Participant 8, post-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-ERK: Participant 9, pre-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-ERK: Participant 9, post-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-ERK: Participant 10, pre-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-ERK: Participant 10, post-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-AKT: Participant 1, pre-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-AKT, Participant 1, post-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-AKT: Participant 2, pre-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-AKT, Participant 2, post-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-AKT: Participant 3, pre-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-AKT, Participant 3, post-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-AKT: Participant 4, pre-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-AKT, Participant 4, post-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-AKT: Participant 5, pre-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-AKT, Participant 5, post-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-AKT: Participant 6, pre-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-AKT, Participant 6, post-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-AKT: Participant 7, pre-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-AKT, Participant 7, post-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-AKT: Participant 8, pre-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-AKT, Participant 8, post-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-AKT: Participant 9, pre-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-AKT, Participant 9, post-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-AKT: Participant 10, pre-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-AKT, Participant 10, post-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) in Part C</title>
        <description>OS is defined as the interval of time between the date of randomization until the date of death due to any cause. For the participants who did not die, overall survival was censored at the date of last contact. When calculating overall survival, deaths following crossover were included.</description>
        <time_frame>From the date of randomization until date of death due to any cause (up to approximately 17 months)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: Dabrafenib 150 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID.</description>
          </group>
          <group group_id="O2">
            <title>Part C: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD.</description>
          </group>
          <group group_id="O3">
            <title>Part C: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) in Part C</title>
          <description>OS is defined as the interval of time between the date of randomization until the date of death due to any cause. For the participants who did not die, overall survival was censored at the date of last contact. When calculating overall survival, deaths following crossover were included.</description>
          <population>ITT Population</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="13.4">The data cut-off date was triggered by at least 70% PFS events in Part C. At the time of data cut, the OS data was not yet mature.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="14.5">The data cut-off date was triggered by at least 70% PFS events in Part C. At the time of data cut, the OS data was not yet mature.</measurement>
                    <measurement group_id="O3" value="NA">The data cut-off date was triggered by at least 70% PFS events in Part C. At the time of data cut, the OS data was not yet mature.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentrations of Dabrafenib and Its Metabolites in Part C</title>
        <description>Plasma concentrations of dabrafenib and its metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) were assesed following daily dose of dabrafenib and trametinib.</description>
        <time_frame>Day 15, Week 8, Week 16, Week 24, Week 32, Week 40, Week 48, and Week 56</time_frame>
        <population>PK Population. Only those participants who were available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: Dabrafenib 150 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID.</description>
          </group>
          <group group_id="O2">
            <title>Part C: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD.</description>
          </group>
          <group group_id="O3">
            <title>Part C: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentrations of Dabrafenib and Its Metabolites in Part C</title>
          <description>Plasma concentrations of dabrafenib and its metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) were assesed following daily dose of dabrafenib and trametinib.</description>
          <population>PK Population. Only those participants who were available at the indicated time points were analyzed.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15, GSK2118436, n=49, 53, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.3" lower_limit="9" upper_limit="2420"/>
                    <measurement group_id="O2" value="68.2" lower_limit="0" upper_limit="1555"/>
                    <measurement group_id="O3" value="66.3" lower_limit="7" upper_limit="1804"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, GSK2118436, n=41, 47, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.6" lower_limit="3" upper_limit="1841"/>
                    <measurement group_id="O2" value="69.8" lower_limit="0" upper_limit="946"/>
                    <measurement group_id="O3" value="50.5" lower_limit="0" upper_limit="1696"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16, GSK2118436, n= 46, 46, 45</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.4" lower_limit="0" upper_limit="1865"/>
                    <measurement group_id="O2" value="66.7" lower_limit="0" upper_limit="1774"/>
                    <measurement group_id="O3" value="82.9" lower_limit="2" upper_limit="3033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, GSK2118436, n=28, 36, 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.3" lower_limit="4" upper_limit="594"/>
                    <measurement group_id="O2" value="66.2" lower_limit="1" upper_limit="2684"/>
                    <measurement group_id="O3" value="93.3" lower_limit="7" upper_limit="741"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32, GSK2118436, n=18, 30, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.6" lower_limit="1" upper_limit="500"/>
                    <measurement group_id="O2" value="57.1" lower_limit="0" upper_limit="1424"/>
                    <measurement group_id="O3" value="66.4" lower_limit="0" upper_limit="2042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40, GSK2118436, n=11, 27, 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="229" lower_limit="5" upper_limit="714"/>
                    <measurement group_id="O2" value="97.6" lower_limit="19" upper_limit="2597"/>
                    <measurement group_id="O3" value="150.9" lower_limit="0" upper_limit="1624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, GSK2118436, n=5, 14, 19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.7" lower_limit="13" upper_limit="132"/>
                    <measurement group_id="O2" value="105.6" lower_limit="0" upper_limit="1322"/>
                    <measurement group_id="O3" value="107.7" lower_limit="3" upper_limit="806"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56, GSK2118436, n=2, 10, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.4" lower_limit="25" upper_limit="68"/>
                    <measurement group_id="O2" value="44.5" lower_limit="0" upper_limit="6646"/>
                    <measurement group_id="O3" value="193.8" lower_limit="3" upper_limit="413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, GSK2285403, n=49, 53, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.7" lower_limit="14" upper_limit="1337"/>
                    <measurement group_id="O2" value="71.8" lower_limit="2" upper_limit="1220"/>
                    <measurement group_id="O3" value="90.5" lower_limit="10" upper_limit="995"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, GSK2285403, n=41, 47, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.2" lower_limit="3" upper_limit="2041"/>
                    <measurement group_id="O2" value="80.4" lower_limit="0" upper_limit="769"/>
                    <measurement group_id="O3" value="90.6" lower_limit="0" upper_limit="757"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16, GSK2285403, n=46, 46, 45</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.4" lower_limit="0" upper_limit="2090"/>
                    <measurement group_id="O2" value="81.9" lower_limit="0" upper_limit="995"/>
                    <measurement group_id="O3" value="114.7" lower_limit="3" upper_limit="2563"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, GSK2285403, n= 28, 36, 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.0" lower_limit="4" upper_limit="616"/>
                    <measurement group_id="O2" value="88.1" lower_limit="0" upper_limit="1689"/>
                    <measurement group_id="O3" value="130.2" lower_limit="9" upper_limit="529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32, GSK2285403, n=18, 30, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5" lower_limit="3" upper_limit="890"/>
                    <measurement group_id="O2" value="86.7" lower_limit="0" upper_limit="808"/>
                    <measurement group_id="O3" value="87.4" lower_limit="0" upper_limit="973"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40, GSK2285403, n=11, 27, 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="263.8" lower_limit="7" upper_limit="693"/>
                    <measurement group_id="O2" value="143.5" lower_limit="16" upper_limit="870"/>
                    <measurement group_id="O3" value="136.2" lower_limit="0" upper_limit="1665"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, GSK2285403, n=5, 14, 19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.3" lower_limit="32" upper_limit="241"/>
                    <measurement group_id="O2" value="93.6" lower_limit="0" upper_limit="898"/>
                    <measurement group_id="O3" value="146.4" lower_limit="2" upper_limit="418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56, GSK2285403, n=2, 10, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.3" lower_limit="45" upper_limit="51"/>
                    <measurement group_id="O2" value="92.9" lower_limit="0" upper_limit="1841"/>
                    <measurement group_id="O3" value="141.5" lower_limit="7" upper_limit="755"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, GSK2298683, n=49, 53, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3493" lower_limit="1381" upper_limit="16820"/>
                    <measurement group_id="O2" value="3043.3" lower_limit="199" upper_limit="8562"/>
                    <measurement group_id="O3" value="3145.8" lower_limit="428" upper_limit="16240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, GSK2298683, n=41, 43, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3149.7" lower_limit="238" upper_limit="13330"/>
                    <measurement group_id="O2" value="3238.4" lower_limit="20" upper_limit="7686"/>
                    <measurement group_id="O3" value="3010" lower_limit="31" upper_limit="13130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16, GSK2298683, n= 46, 46, 45</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3497.9" lower_limit="21" upper_limit="9952"/>
                    <measurement group_id="O2" value="2946.1" lower_limit="0" upper_limit="8782"/>
                    <measurement group_id="O3" value="2756.5" lower_limit="44" upper_limit="14004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, GSK2298683, n=28, 36, 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2876.5" lower_limit="500" upper_limit="8635"/>
                    <measurement group_id="O2" value="3365.4" lower_limit="25" upper_limit="7482"/>
                    <measurement group_id="O3" value="3193.7" lower_limit="133" upper_limit="6531"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32, GSK2298683, n=18, 30, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2699.9" lower_limit="447" upper_limit="14341"/>
                    <measurement group_id="O2" value="3267.1" lower_limit="0" upper_limit="9278"/>
                    <measurement group_id="O3" value="3046.8" lower_limit="50" upper_limit="9077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40, GSK2298683, n=11, 27, 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4410.6" lower_limit="1023" upper_limit="14258"/>
                    <measurement group_id="O2" value="3694.7" lower_limit="1900" upper_limit="7663"/>
                    <measurement group_id="O3" value="3492.8" lower_limit="0" upper_limit="12550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, GSK2298683, n=5, 14, 19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3554.9" lower_limit="1889" upper_limit="7148"/>
                    <measurement group_id="O2" value="4146.9" lower_limit="0" upper_limit="8351"/>
                    <measurement group_id="O3" value="3936.1" lower_limit="464" upper_limit="12239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56, GSK2298683, n=2, 10, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2032.2" lower_limit="1102" upper_limit="2963"/>
                    <measurement group_id="O2" value="3843.5" lower_limit="374" upper_limit="6866"/>
                    <measurement group_id="O3" value="2904.9" lower_limit="1305" upper_limit="4673"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, GSK2167542, n=49, 53, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="247.9" lower_limit="95" upper_limit="955"/>
                    <measurement group_id="O2" value="288" lower_limit="49" upper_limit="1164"/>
                    <measurement group_id="O3" value="289.3" lower_limit="72" upper_limit="1140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, GSK2167542, n=41, 47, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="239.5" lower_limit="19" upper_limit="1092"/>
                    <measurement group_id="O2" value="275.2" lower_limit="3" upper_limit="983"/>
                    <measurement group_id="O3" value="262.4" lower_limit="0" upper_limit="9876"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16, GSK2167542, n=46, 46, 45</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="244" lower_limit="1" upper_limit="772"/>
                    <measurement group_id="O2" value="204.4" lower_limit="0" upper_limit="922"/>
                    <measurement group_id="O3" value="243.8" lower_limit="3" upper_limit="1049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, GSK2167542, n=28, 36, 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="225.6" lower_limit="48" upper_limit="899"/>
                    <measurement group_id="O2" value="247.2" lower_limit="4" upper_limit="990"/>
                    <measurement group_id="O3" value="254.6" lower_limit="3" upper_limit="846"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32, GSK2167542, n=18, 30, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171" lower_limit="19" upper_limit="544"/>
                    <measurement group_id="O2" value="255.4" lower_limit="0" upper_limit="698"/>
                    <measurement group_id="O3" value="289.3" lower_limit="2" upper_limit="962"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40, GSK2167542, n=11, 27, 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="222.2" lower_limit="95" upper_limit="639"/>
                    <measurement group_id="O2" value="249.3" lower_limit="55" upper_limit="674"/>
                    <measurement group_id="O3" value="268.9" lower_limit="0" upper_limit="910"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, GSK2167542, n=5, 14, 19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204.5" lower_limit="145" upper_limit="286"/>
                    <measurement group_id="O2" value="232" lower_limit="0" upper_limit="915"/>
                    <measurement group_id="O3" value="260.9" lower_limit="81" upper_limit="886"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56, GSK2167542, n=5, 10, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171.8" lower_limit="116" upper_limit="228"/>
                    <measurement group_id="O2" value="250" lower_limit="28" upper_limit="851"/>
                    <measurement group_id="O3" value="462.1" lower_limit="107" upper_limit="663"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentrations of Trametinib in Part C</title>
        <description>Plasma concentrations of trametinib was assessed following daily dose of dabrafenib and trametinib.</description>
        <time_frame>Day 15, Week 8, Week 16, Week 24, Week 32, Week 40, Week 48, and Week 56</time_frame>
        <population>PK Population. Only those participants who were available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: Dabrafenib 150 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID.</description>
          </group>
          <group group_id="O2">
            <title>Part C: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD.</description>
          </group>
          <group group_id="O3">
            <title>Part C: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentrations of Trametinib in Part C</title>
          <description>Plasma concentrations of trametinib was assessed following daily dose of dabrafenib and trametinib.</description>
          <population>PK Population. Only those participants who were available at the indicated time points were analyzed.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15, n=49, 53, 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="5.86" lower_limit="3.4" upper_limit="11.3"/>
                    <measurement group_id="O3" value="9.35" lower_limit="4.8" upper_limit="26.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, n=41, 45, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="13.9"/>
                    <measurement group_id="O2" value="6.70" lower_limit="2.0" upper_limit="9.6"/>
                    <measurement group_id="O3" value="10.3" lower_limit="0" upper_limit="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16, n=46, 43, 45</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="9.8"/>
                    <measurement group_id="O2" value="6.99" lower_limit="0" upper_limit="20.7"/>
                    <measurement group_id="O3" value="9.87" lower_limit="1.1" upper_limit="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, n=29, 35, 41</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="19.7"/>
                    <measurement group_id="O2" value="5.99" lower_limit="0" upper_limit="11.2"/>
                    <measurement group_id="O3" value="9.54" lower_limit="0.5" upper_limit="27.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32, n=18, 30, 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="5.77" lower_limit="0.7" upper_limit="11.6"/>
                    <measurement group_id="O3" value="9.74" lower_limit="0" upper_limit="51.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40, n=11, 26, 27</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="7.11" lower_limit="2.2" upper_limit="16.7"/>
                    <measurement group_id="O3" value="10.1" lower_limit="0" upper_limit="26.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, n=5, 14, 19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="5.62" lower_limit="0" upper_limit="14.3"/>
                    <measurement group_id="O3" value="10.3" lower_limit="0" upper_limit="35.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56, n=2, 10, 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="9.90" lower_limit="3.4" upper_limit="16.9"/>
                    <measurement group_id="O3" value="8.60" lower_limit="0" upper_limit="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oral Clearance (CL/F) of Dabrafenib and Trametinib</title>
        <description>Oral clearance (CL/F) of dabrafenib and trametinib were assessed using a population approach. Oral clearance (CL/F) is defined as the apparent volume of plasma in the vascular compartment cleared of drug per unit time by the processes of metabolism and excretion. For dabrafenib, population CL/F is defined as inducible and non-inducible CL/F. As dabrafenib induces its own metabolism, total oral clearance at steady state includes a non-induced (Day 1) component and an induced component, as estimated by a population PK model.</description>
        <time_frame>Day 15, Week 8, Week 16, Week 24, Week 32, Week 40, and Week 48</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: Dabrafenib 150 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID.</description>
          </group>
          <group group_id="O2">
            <title>Part C: Trametinib</title>
            <description>Participants received Trametinib 1 mg or 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Oral Clearance (CL/F) of Dabrafenib and Trametinib</title>
          <description>Oral clearance (CL/F) of dabrafenib and trametinib were assessed using a population approach. Oral clearance (CL/F) is defined as the apparent volume of plasma in the vascular compartment cleared of drug per unit time by the processes of metabolism and excretion. For dabrafenib, population CL/F is defined as inducible and non-inducible CL/F. As dabrafenib induces its own metabolism, total oral clearance at steady state includes a non-induced (Day 1) component and an induced component, as estimated by a population PK model.</description>
          <population>PK Population</population>
          <units>Liters per hour (L/hr)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-inducible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4" lower_limit="17.6" upper_limit="21.2"/>
                    <measurement group_id="O2" value="5.07" lower_limit="4.83" upper_limit="5.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inducible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="19.2" upper_limit="20.8"/>
                    <measurement group_id="O2" value="NA">CL/F is not induced for trametinib.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oral Volume of Distribution (V/F) of Dabrafenib and Trametinib</title>
        <description>Oral volume of distribution (V/F) of dabrafenib and trametinib were assessed using a population approach. Oral volume of distribution (V/F) is defined as the apparent volume of distribution in the central compartment.</description>
        <time_frame>Day 15, Week 8, Week 16, Week 24, Week 32, Week 40, and Week 48</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: Dabrafenib 150 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID.</description>
          </group>
          <group group_id="O2">
            <title>Part C: Trametinib</title>
            <description>Participants received Trametinib 1 mg or 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Oral Volume of Distribution (V/F) of Dabrafenib and Trametinib</title>
          <description>Oral volume of distribution (V/F) of dabrafenib and trametinib were assessed using a population approach. Oral volume of distribution (V/F) is defined as the apparent volume of distribution in the central compartment.</description>
          <population>PK Population</population>
          <units>Liters (L)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.8" lower_limit="73.9" upper_limit="87.7"/>
                    <measurement group_id="O2" value="184" lower_limit="158" upper_limit="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax of Dabrafenib Metabolites in Part D</title>
        <description>The maximum concentration (Cmax) of dabrafenib metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) after single and repeat doses of DAB alone and in combination with trametinib was measured at Day 1 and Day 21.</description>
        <time_frame>Day 1: pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 24 hours post dose. Day 21: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 10 hours post-dose</time_frame>
        <population>PK Population. Only participants who were available at the indicated timepoints were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part D: Dabrafenib 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
          <group group_id="O4">
            <title>Part D: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Dabrafenib Metabolites in Part D</title>
          <description>The maximum concentration (Cmax) of dabrafenib metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) after single and repeat doses of DAB alone and in combination with trametinib was measured at Day 1 and Day 21.</description>
          <population>PK Population. Only participants who were available at the indicated timepoints were analyzed.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GSK2285403, Day 1,n=15, 14, 15, 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="525" lower_limit="429" upper_limit="643"/>
                    <measurement group_id="O2" value="1055" lower_limit="705" upper_limit="1579"/>
                    <measurement group_id="O3" value="597" lower_limit="474" upper_limit="752"/>
                    <measurement group_id="O4" value="1363" lower_limit="300" upper_limit="2066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2285403, Day 21, n=14, 11, 14, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="596" lower_limit="501" upper_limit="709"/>
                    <measurement group_id="O2" value="1203" lower_limit="906" upper_limit="1599"/>
                    <measurement group_id="O3" value="696" lower_limit="551" upper_limit="880"/>
                    <measurement group_id="O4" value="1120" lower_limit="725" upper_limit="1730"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2298683, Day 1, n=15, 14, 15, 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1475" lower_limit="1249" upper_limit="1741"/>
                    <measurement group_id="O2" value="2268" lower_limit="1595" upper_limit="3223"/>
                    <measurement group_id="O3" value="1478" lower_limit="1197" upper_limit="1824"/>
                    <measurement group_id="O4" value="2551" lower_limit="1756" upper_limit="3707"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2298683, Day 21, n=14, 11, 14, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3637" lower_limit="3119" upper_limit="4242"/>
                    <measurement group_id="O2" value="6743" lower_limit="5133" upper_limit="8859"/>
                    <measurement group_id="O3" value="4158" lower_limit="3136" upper_limit="5514"/>
                    <measurement group_id="O4" value="6319" lower_limit="4725" upper_limit="8450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2167542, Day 1, n=13, 13, 15, 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.1" lower_limit="30" upper_limit="84"/>
                    <measurement group_id="O2" value="68.6" lower_limit="36" upper_limit="129"/>
                    <measurement group_id="O3" value="61.2" lower_limit="41" upper_limit="91"/>
                    <measurement group_id="O4" value="86.3" lower_limit="48" upper_limit="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2167542, Day 21, n=14, 11, 14, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="210" lower_limit="154" upper_limit="285"/>
                    <measurement group_id="O2" value="355" lower_limit="268" upper_limit="470"/>
                    <measurement group_id="O3" value="289" lower_limit="201" upper_limit="416"/>
                    <measurement group_id="O4" value="440" lower_limit="303" upper_limit="637"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Tmax of Dabrafenib Metabolites in Part D</title>
        <description>The time to Cmax (tmax) of DAB metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) after single and repeat doses of DAB alone and in combination with trametinib was measured at Day 1 and Day 21.</description>
        <time_frame>Day 1: pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 24 hours post dose. Day 21: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 10 hours post-dose</time_frame>
        <population>PK Population. Only participants who were available at the indicated timepoints were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part D: Dabrafenib 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
          <group group_id="O4">
            <title>Part D: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>The Tmax of Dabrafenib Metabolites in Part D</title>
          <description>The time to Cmax (tmax) of DAB metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) after single and repeat doses of DAB alone and in combination with trametinib was measured at Day 1 and Day 21.</description>
          <population>PK Population. Only participants who were available at the indicated timepoints were analyzed.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GSK2285403, Day 1, n=15, 14, 15, 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="1.50" upper_limit="4.00"/>
                    <measurement group_id="O2" value="3.51" lower_limit="2.00" upper_limit="6.18"/>
                    <measurement group_id="O3" value="3.00" lower_limit="2.00" upper_limit="6.02"/>
                    <measurement group_id="O4" value="2.07" lower_limit="1.50" upper_limit="10.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2285403, Day 21, n=14, 11, 14, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.50" upper_limit="3.00"/>
                    <measurement group_id="O2" value="2.00" lower_limit="1.42" upper_limit="3.00"/>
                    <measurement group_id="O3" value="2.00" lower_limit="1.47" upper_limit="4.00"/>
                    <measurement group_id="O4" value="2.00" lower_limit="1.00" upper_limit="3.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2298683, Day 1, n=15, 14, 15, 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="5.98" upper_limit="10.1"/>
                    <measurement group_id="O2" value="8.93" lower_limit="4.00" upper_limit="24.0"/>
                    <measurement group_id="O3" value="10.0" lower_limit="6.00" upper_limit="24.0"/>
                    <measurement group_id="O4" value="8.00" lower_limit="4.07" upper_limit="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2298683, Day 21, n=14, 11, 14, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" lower_limit="3.00" upper_limit="8.00"/>
                    <measurement group_id="O2" value="4.00" lower_limit="3.00" upper_limit="6.00"/>
                    <measurement group_id="O3" value="5.98" lower_limit="2.00" upper_limit="10.00"/>
                    <measurement group_id="O4" value="4.00" lower_limit="3.00" upper_limit="6.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2167542, Day 1, n=13, 13, 15, 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" lower_limit="8.00" upper_limit="24.1"/>
                    <measurement group_id="O2" value="24.0" lower_limit="6.00" upper_limit="24.6"/>
                    <measurement group_id="O3" value="24.0" lower_limit="23.5" upper_limit="25.0"/>
                    <measurement group_id="O4" value="24.0" lower_limit="10.0" upper_limit="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2167542, Day 21, n=14, 11, 14, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" lower_limit="0" upper_limit="10.0"/>
                    <measurement group_id="O2" value="2.00" lower_limit="0.50" upper_limit="10.0"/>
                    <measurement group_id="O3" value="2.00" lower_limit="1.00" upper_limit="10.00"/>
                    <measurement group_id="O4" value="1.75" lower_limit="0" upper_limit="9.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve (AUC) of Dabrafenib Metabolites in Part D</title>
        <description>Area under the concentration-time curve (AUC) from pre-dose to dosing interval (AUC[0-tau]), from pre-dose to the last time of quantifiable concentration (AUC[0-tau]), and from pre-dose extrapolated to infinity (AUC[0-inf]) of DAB metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) after single and repeat doses of DAB alone and in combination with trametinib was measured at Day 1 and Day 21.</description>
        <time_frame>Day 1: pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 24 hours post dose. Day 21: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 10 hours post-dose</time_frame>
        <population>PK Population. Only participants who were available at the indicated timepoints were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part D: Dabrafenib 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
          <group group_id="O4">
            <title>Part D: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve (AUC) of Dabrafenib Metabolites in Part D</title>
          <description>Area under the concentration-time curve (AUC) from pre-dose to dosing interval (AUC[0-tau]), from pre-dose to the last time of quantifiable concentration (AUC[0-tau]), and from pre-dose extrapolated to infinity (AUC[0-inf]) of DAB metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) after single and repeat doses of DAB alone and in combination with trametinib was measured at Day 1 and Day 21.</description>
          <population>PK Population. Only participants who were available at the indicated timepoints were analyzed.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GSK2285403, AUC(0-tau), Day 1, n=15, 14, 15, 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3134" lower_limit="2533" upper_limit="3877"/>
                    <measurement group_id="O2" value="5950" lower_limit="4045" upper_limit="8753"/>
                    <measurement group_id="O3" value="3694" lower_limit="2903" upper_limit="4700"/>
                    <measurement group_id="O4" value="6524" lower_limit="4520" upper_limit="9416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2285403, AUC(0-inf), Day 1, n=15, 14, 15, 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3963" lower_limit="3147" upper_limit="4990"/>
                    <measurement group_id="O2" value="7415" lower_limit="4991" upper_limit="11015"/>
                    <measurement group_id="O3" value="5026" lower_limit="3934" upper_limit="6422"/>
                    <measurement group_id="O4" value="7907" lower_limit="5434" upper_limit="11506"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2285403, AUC (0-tau), Day 21, n=14, 11, 14, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2568" lower_limit="2099" upper_limit="3143"/>
                    <measurement group_id="O2" value="4262" lower_limit="3007" upper_limit="6040"/>
                    <measurement group_id="O3" value="2919" lower_limit="2296" upper_limit="3711"/>
                    <measurement group_id="O4" value="4216" lower_limit="2986" upper_limit="5951"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2298683, AUC, (0-tau), Day 1, n=15, 14, 15, 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10396" lower_limit="8388" upper_limit="12885"/>
                    <measurement group_id="O2" value="15952" lower_limit="10532" upper_limit="24160"/>
                    <measurement group_id="O3" value="9575" lower_limit="7143" upper_limit="12835"/>
                    <measurement group_id="O4" value="20935" lower_limit="12430" upper_limit="35259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2298683, AUC (0-t), Day 1, n=15, 14, 15, 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20047" lower_limit="15384" upper_limit="26125"/>
                    <measurement group_id="O2" value="35206" lower_limit="24970" upper_limit="49639"/>
                    <measurement group_id="O3" value="22692" lower_limit="18398" upper_limit="27988"/>
                    <measurement group_id="O4" value="31666" lower_limit="18474" upper_limit="54277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2298683, AUC (0-tau), Day 21, n = 14, 11, 14,</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34283" lower_limit="29189" upper_limit="40266"/>
                    <measurement group_id="O2" value="59340" lower_limit="44595" upper_limit="78960"/>
                    <measurement group_id="O3" value="39672" lower_limit="29504" upper_limit="53343"/>
                    <measurement group_id="O4" value="52712" lower_limit="40084" upper_limit="69318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2167542, AUC(0-tau), Day 1, n=13, 13, 15, 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132" lower_limit="79" upper_limit="219"/>
                    <measurement group_id="O2" value="190" lower_limit="101" upper_limit="356"/>
                    <measurement group_id="O3" value="88.8" lower_limit="56" upper_limit="139"/>
                    <measurement group_id="O4" value="354" lower_limit="228" upper_limit="549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2167542, AUC(0-t) Day 1, n=13, 13, 15, 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="500" lower_limit="271" upper_limit="925"/>
                    <measurement group_id="O2" value="737" lower_limit="385" upper_limit="1410"/>
                    <measurement group_id="O3" value="614" lower_limit="415" upper_limit="906"/>
                    <measurement group_id="O4" value="1316" lower_limit="824" upper_limit="2103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2167542, AUC(0-tau), Day 21, n=14, 11, 14, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1775" lower_limit="1225" upper_limit="2570"/>
                    <measurement group_id="O2" value="2707" lower_limit="2106" upper_limit="3481"/>
                    <measurement group_id="O3" value="2508" lower_limit="1793" upper_limit="3507"/>
                    <measurement group_id="O4" value="3632" lower_limit="2529" upper_limit="5216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Cmax Assessment of Trametinib in Part D</title>
        <description>Cmax of trametinib after single and repeat dose in combination with DAB was observed at Day 1 and Day 21. Blood samples for PK analysis of dabrafenib were obtained at pre-dose Day 1 and Day 21 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours (Day 1 only) post-dose administration. From the plasma concentration-time curve, the PK parameter tmax was determined by standard non-compartmental analysis using WinNonlin.Participants receiving DAB 75 mg to DAB 75 mg + Trametinib 2 mg and those receiving DAB 150 mg to DAB 150 mg + Trametinib 2 mg did not receive Trametinib until Day 29; therefore, Cmax was not analyzed in these participants at Days 1 and 21.</description>
        <time_frame>Day 1: pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 24 hours post dose. Day 21: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 10 hours post-dose</time_frame>
        <population>PK Population. Only participants who were available at the indicated timepoints were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part D: Dabrafenib 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
          <group group_id="O4">
            <title>Part D: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>The Cmax Assessment of Trametinib in Part D</title>
          <description>Cmax of trametinib after single and repeat dose in combination with DAB was observed at Day 1 and Day 21. Blood samples for PK analysis of dabrafenib were obtained at pre-dose Day 1 and Day 21 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours (Day 1 only) post-dose administration. From the plasma concentration-time curve, the PK parameter tmax was determined by standard non-compartmental analysis using WinNonlin.Participants receiving DAB 75 mg to DAB 75 mg + Trametinib 2 mg and those receiving DAB 150 mg to DAB 150 mg + Trametinib 2 mg did not receive Trametinib until Day 29; therefore, Cmax was not analyzed in these participants at Days 1 and 21.</description>
          <population>PK Population. Only participants who were available at the indicated timepoints were analyzed.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, n=0, 0, 15, 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="6.8" lower_limit="5" upper_limit="10"/>
                    <measurement group_id="O4" value="6.6" lower_limit="4" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21, n=0, 0, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="24.1" lower_limit="20" upper_limit="29"/>
                    <measurement group_id="O4" value="22.6" lower_limit="20" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Tmax Assessment of Trametinib in Part D</title>
        <description>The tmax of trametinib after single and repeat dose in combination with dabrafenib (DAB) was observed at Day 1 and Day 21. Blood samples for PK analysis of dabrafenib were obtained at pre-dose Day 1 and Day 21 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours (Day 1 only) post-dose administration. From the plasma concentration-time curve, the PK parameter tmax was determined by standard non-compartmental analysis using WinNonlin.Participants receiving DAB 75 mg to DAB 75 mg + Trametinib 2 mg and those receiving DAB 150 mg to DAB 150 mg + Trametinib 2 mg did not receive Trametinib until Day 29; therefore, tmax was not analyzed in these participants at Days 1 and 21.</description>
        <time_frame>Day 1: pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 24 hours post dose. Day 21: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 10 hours post-dose</time_frame>
        <population>PK Population. Only participants who were available at the indicated timepoints were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part D: Dabrafenib 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
          <group group_id="O4">
            <title>Part D: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>The Tmax Assessment of Trametinib in Part D</title>
          <description>The tmax of trametinib after single and repeat dose in combination with dabrafenib (DAB) was observed at Day 1 and Day 21. Blood samples for PK analysis of dabrafenib were obtained at pre-dose Day 1 and Day 21 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours (Day 1 only) post-dose administration. From the plasma concentration-time curve, the PK parameter tmax was determined by standard non-compartmental analysis using WinNonlin.Participants receiving DAB 75 mg to DAB 75 mg + Trametinib 2 mg and those receiving DAB 150 mg to DAB 150 mg + Trametinib 2 mg did not receive Trametinib until Day 29; therefore, tmax was not analyzed in these participants at Days 1 and 21.</description>
          <population>PK Population. Only participants who were available at the indicated timepoints were analyzed.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, n=0, 0, 15, 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="2.00" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O4" value="1.50" lower_limit="1.00" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21, n=0, 0, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="2.00" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O4" value="2.00" lower_limit="1.50" upper_limit="3.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve Assessment of Trametinib in Part D</title>
        <description>AUC(0-tau) after single and repeat dose of trametinib alone and in combination with dabrafenib was observed at Day 1 and Day 21. Blood samples for PK analysis of dabrafenib were obtained at pre-dose Day 1 and Day 21 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours (Day 1 only) post-dose administration. From the plasma concentration-time curve, the PK parameter tmax was determined by standard non-compartmental analysis using WinNonlin.Participants receiving DAB 75 mg to DAB 75 mg + Trametinib 2 mg and those receiving DAB 150 mg to DAB 150 mg + Trametinib 2 mg did not receive Trametinib until Day 29; therefore, AUC(0-tau) was not analyzed in these participants at Days 1 and 21.</description>
        <time_frame>Day 1: pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 24 hours post dose. Day 21: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 10 hours post-dose</time_frame>
        <population>PK Population. Only participants who were available at the indicated timepoints were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part D: Dabrafenib 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
          <group group_id="O4">
            <title>Part D: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve Assessment of Trametinib in Part D</title>
          <description>AUC(0-tau) after single and repeat dose of trametinib alone and in combination with dabrafenib was observed at Day 1 and Day 21. Blood samples for PK analysis of dabrafenib were obtained at pre-dose Day 1 and Day 21 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours (Day 1 only) post-dose administration. From the plasma concentration-time curve, the PK parameter tmax was determined by standard non-compartmental analysis using WinNonlin.Participants receiving DAB 75 mg to DAB 75 mg + Trametinib 2 mg and those receiving DAB 150 mg to DAB 150 mg + Trametinib 2 mg did not receive Trametinib until Day 29; therefore, AUC(0-tau) was not analyzed in these participants at Days 1 and 21.</description>
          <population>PK Population. Only participants who were available at the indicated timepoints were analyzed.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, n=0, 0, 15, 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="53.4" lower_limit="40" upper_limit="72"/>
                    <measurement group_id="O4" value="50.7" lower_limit="39" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21, n=0, 0, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="366" lower_limit="305" upper_limit="439"/>
                    <measurement group_id="O4" value="356" lower_limit="318" upper_limit="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With the Best Overall Response as Assessed by the Investigator in Participants in Part D</title>
        <description>Best overall response is defined as complete response (CR: the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 millimeter [mm] in the short axis.) or partial response (PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]). To be assigned a status of PR or CR, a confirmatory disease assessment should be performed no less than 28 days after the criteria for response are first met. Response was evaluated by an investigator as per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.</description>
        <time_frame>From the date of first dose of study medication to the first documented evidence of a confirmed complete response or partial response (up to approximately 280 days )</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part D: Dabrafenib 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
          <group group_id="O4">
            <title>Part D: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Best Overall Response as Assessed by the Investigator in Participants in Part D</title>
          <description>Best overall response is defined as complete response (CR: the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 millimeter [mm] in the short axis.) or partial response (PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]). To be assigned a status of PR or CR, a confirmatory disease assessment should be performed no less than 28 days after the criteria for response are first met. Response was evaluated by an investigator as per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response as Assessed by the Investigator in Part D</title>
        <description>Duration of response for participants with either a CR (the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 mm in the short axis.) or PR (at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]) is defined as the time from the first documented evidence of a PR or CR until the first documented sign of disease progression (PD) or death due to any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm.</description>
        <time_frame>First documented evidence of PR or CR until the earlier of date of disease progression or date of death due to any cause (up to approximately 13 months)</time_frame>
        <population>ITT Population. Only those participants who had CR or PR were considered.</population>
        <group_list>
          <group group_id="O1">
            <title>Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part D: Dabrafenib 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
          <group group_id="O4">
            <title>Part D: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response as Assessed by the Investigator in Part D</title>
          <description>Duration of response for participants with either a CR (the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 mm in the short axis.) or PR (at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]) is defined as the time from the first documented evidence of a PR or CR until the first documented sign of disease progression (PD) or death due to any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm.</description>
          <population>ITT Population. Only those participants who had CR or PR were considered.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="3.7" upper_limit="9.7"/>
                    <measurement group_id="O2" value="7.4" lower_limit="5.6">At the time of this report, the data was not yet mature; therefore, the upper limit (UL) of the CI could not be estimated.</measurement>
                    <measurement group_id="O3" value="5.6" lower_limit="3.7" upper_limit="7.9"/>
                    <measurement group_id="O4" value="NA" lower_limit="5.6">At the time of this report, the data was not yet mature; therefore, the median and the upper limit (UL) of the CI could not be estimated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS) as Assessed by the Investigator in Part D</title>
        <description>PFS is defined as the interval between the first dose of study medication and the earliest date of PD or death due to any cause. PD was based on radiographic or photographic evidence, and assessments were made by the investigator according to RECIST, version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm.</description>
        <time_frame>From the date of randomization to the earliest date of disease progression (PD) or death due to any cause (up to approximately 13 months)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part D: Dabrafenib 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
          <group group_id="O4">
            <title>Part D: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS) as Assessed by the Investigator in Part D</title>
          <description>PFS is defined as the interval between the first dose of study medication and the earliest date of PD or death due to any cause. PD was based on radiographic or photographic evidence, and assessments were made by the investigator according to RECIST, version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm.</description>
          <population>ITT Population</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" lower_limit="5.5" upper_limit="10.9"/>
                    <measurement group_id="O2" value="9.3" lower_limit="5.7">At the time of this report, the data was not yet mature; therefore, the upper limit (UL) of the CI could not be estimated.</measurement>
                    <measurement group_id="O3" value="7.5" lower_limit="6.4" upper_limit="10.3"/>
                    <measurement group_id="O4" value="NA" lower_limit="7.0">At the time of this report, the data was not yet mature; therefore, the median and the upper limit (UL) of the CI could not be estimated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival in Part D</title>
        <description>OS is defined as the interval of time between the date of randomization until the date of death due to any cause. For the participants who did not die, overall survival was censored at the date of last contact. Validation of OS is currently ongoing; thus, data are not available at this time.</description>
        <time_frame>From the date of first dose until date of death due to any cause (up to approximately 14 months)</time_frame>
        <posting_date>04/2019</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events (SAEs) and non-serious AEs were collected from Baseline (Day 1) until Follow-up visit (up to approximately 103 weeks).</time_frame>
      <desc>SAEs and non-serious Aes were collected in the All Treated Population which was based on the actual treatment received. For Part D, 3 participants received treatment that differed from the randomized treatment. For Part C: 1 participant received treatment that differed from the randomized treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Part A: Dabrafenib 75 mg + Trametinib 2 mg</title>
          <description>Participants received a single dose of dabrafenib 75 mg gelatin capsules with repeat dose trametinib (Day 15).</description>
        </group>
        <group group_id="E2">
          <title>Part B: Dabrafenib 75 mg + Trametinib 1 mg</title>
          <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 75 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available pharmacokinetic (PK), safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on dose-limiting toxicities (DLTs) occurring during the first 3 weeks of treatment.</description>
        </group>
        <group group_id="E3">
          <title>Part B: Dabrafenib 150 mg + Trametinib 1 mg</title>
          <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors and participants who had salivary ductal cancer received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
        </group>
        <group group_id="E4">
          <title>Part B: Dabrafenib 150 mg + Trametinib 1.5 mg</title>
          <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 150 mg gelatin capsules BID and trametinib 1.5 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
        </group>
        <group group_id="E5">
          <title>Part B: Dabrafenib 150 mg + Trametinib 2 mg</title>
          <description>Melanoma BRAF-positive participants who received prior treatment with BRAF inhibitors and participants who had colorectal cancer and BRAFi naïve melanoma received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD as continuous daily dosing. Dose escalation did not proceed beyond these doses of dabrafenib and trametinib.</description>
        </group>
        <group group_id="E6">
          <title>Part C: Dabrafenib 150 mg</title>
          <description>Participants received dabrafenib 150 mg gelatin capsules BID.</description>
        </group>
        <group group_id="E7">
          <title>Part C (Crossover): Dabrafenib 150 mg + Trametinib 2 mg</title>
          <description>Participants who received dabrafenib 150 mg capsules BID alone in the Randomized Phase were given the opportunity to receive combination dosing of dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD upon disease progression with approval of the GlaxoSmithKline (GSK) Medical Monitor.</description>
        </group>
        <group group_id="E8">
          <title>Part C: Dabrafenib 150 mg + Trametinib 1 mg</title>
          <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD.</description>
        </group>
        <group group_id="E9">
          <title>Part C: Dabrafenib 150 mg + Trametinib 2 mg</title>
          <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD.</description>
        </group>
        <group group_id="E10">
          <title>Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg</title>
          <description>Participants received dabrefinib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
        </group>
        <group group_id="E11">
          <title>Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg</title>
          <description>Participants received dabrefinib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
        </group>
        <group group_id="E12">
          <title>Part D: Dabrafenib 75 mg + Trametinib 2 mg</title>
          <description>Participants received dabrefinib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
        </group>
        <group group_id="E13">
          <title>Part D: Dabrafenib 150 mg + Trametinib 2 mg</title>
          <description>Participants received dabrefinib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="44" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="20" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="34" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="12" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="22" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="25" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Idiopathic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Addison's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Chorioretinopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Optic ischaemic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Duodenal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Large intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Colonic obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Abdominal wall haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="14" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="12" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="16" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="10" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="15" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Gallbladder disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Cytokine release syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Device related sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hepatic infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Endocarditis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pseudomonal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Streptococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pneumonia necrotising</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Allergic transfusion reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Metastases to spine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Keratoacanthoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Glioblastoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Malignant ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Neuritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Brain stem haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Intracranial hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Facial paresis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Complex partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Renal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper airway obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Vena cava thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="76" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="53" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="40" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="53" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="55" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="15" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="15" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="41" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="37" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="7" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Lymph node pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Intracardiac mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Dermoid cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Vitreous detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Chorioretinopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Iritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Asthenopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Chalazion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Keratopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Lacrimation decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="38" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="25" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="24" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="8" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="22" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="17" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="23" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="22" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="18" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="16" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="14" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="20" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="15" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="7" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="12" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="9" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Mesenteric artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Oral mucosa erosion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="50" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="34" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="37" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="15" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="16" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="39" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="31" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="29" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="21" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="12" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="35" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="20" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="29" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="11" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="9" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="16" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="7" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Axillary pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nodule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Xerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Periorbital infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Anorectal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Infected bites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Contrast media reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Wound haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Carbon dioxide increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Blood magnesium decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="16" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="12" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="8" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypermagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Impaired fasting glucose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="24" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="15" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="9" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="14" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="14" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="11" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Sensation of heaviness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Acrochordon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Keratoacanthoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Juvenile melanoma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Metastatic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="20" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="16" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="12" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="10" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hyperaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Motor dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nystagmus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="10" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Emotional disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Mood altered</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Thinking abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Micturition urgency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="16" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="11" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Paranasal sinus hypersecretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Upper-airway cough syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nasal dryness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Painful respiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="15" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="12" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="15" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="13" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="8" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="10" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Erythema nodosum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hair texture abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Papule</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Keratosis pilaris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Transient acantholytic dermatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Skin hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Onychoclasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Skin discolouration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Palmar erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pigmentation disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Skin haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Blood pressure fluctuation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Disclosure Office</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>Novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

